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Serotonin is a vital neurotransmitter whose exact roles are ill-defined. Dysfunctions 
in serotonin signaling are thought to underlie a myriad of neurological problems including 
depression and autism spectrum disorder (ASD).  Prior to investigating serotonin’s role in 
disease states, one must understand more about the functionality of serotonin in healthy in 
vivo models. To study serotonin in vivo, fast-scan cyclic voltammetry (FSCV) and fast-
scan controlled adsorption voltammetry (FSCAV) are employed to measure evoked and 
basal serotonin concentration, respectively. These methods, combined with mathematical 
modeling, provide information regarding regulatory mechanisms of serotonin 
neurotransmission. FSCV and FSCAV are first applied to characterize serotonin chemistry 
in the medial prefrontal cortex (mPFC), a brain region with abundant serotonin projections 
and associations with various diseases. In this region, we discover two unique populations 
of serotonin axons terminating in discrete reuptake domains. The mPFC serotonin signals 
are unique when compared to previously established brain regions. Mathematical modeling 
of the regions provides a unique tool to determine local tissue architecture. Establishing a 
model of serotonin neurotransmission in the mPFC of healthy mice allows us to begin to 
explore alterations during disease states and determine etiology. 
            Peripheral serotonin dysfunction is a common phenotype of ASD despite the 
underlying pathophysiology of this disorder remaining poorly understood. ASD is thought 
to result from a combination of genetic and environmental risk factors. To better 
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understand serotonin’s role in the brain during ASD, we investigate two genetic ASD 
models and find similar alterations in evoked serotonin reuptake. To evaluate the 
contribution of lead as a risk factor for ASD, we use a low dose perinatal exposure model. 
Though no convincing evidence of ASD typical behaviors is induced by this exposure 
paradigm, acute effects at such low doses provides cause for concern and implies that 
compensatory mechanisms are employed to maintain the homeostasis of serotonin during 
long-term exposures. 
            In this dissertation, I present evidence for unique serotonin transmission in the 
mPFC and establish further evidence of serotonin neurotransmission disruptions in mouse 
ASD models. I evaluate lead for its effects on the serotonin system and provided support 
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Serotonin (5-hydroxytryptamine, or 5-HT) is an essential biological molecule 
present primarily in the gut, blood, and brain. The function of serotonin differs depending 
on the area of the body. In the gut, this molecule primarily regulates intestinal movements 
and in the blood it facilitates hemostasis and blood clotting1. In the brain, serotonin acts as 
a neurotransmitter, playing roles in numerous functions, including sleep, mood, appetite, 
and anxiety to name just a few2, 3. The way in which serotonin regulates brain function is 
ill-understood. This shortcoming primarily because it is difficult to measure serotonin in 
the brain. 
Serotonin has 7 distinct known receptor families (each with multiple sub-types)4 
and can be reuptaken by any of the monoamine transporters, as well as the organic cation 
transporter5. Understanding the role of each of these receptors and transporters has been 
the focus of decades of research. However, understanding how these proteins interact with 
serotonin and each other to regulate this molecule’s transmission is difficult because it 
requires a technique capable of in vivo measurements while causing minimal damage to 
these circuits. The gap in understanding how serotonin contributes to the regulation of 
specific functions has also led to a gap in our understanding of how serotonin contributes 
to diseases in which it is implicated. One such disease is autism spectrum disorder (ASD). 
Abnormalities in serotonin concentration in the peripheral nervous system is well studied6, 
but we know much less about this messenger in the central nervous system.  
 
1.2 AUTISM SPECTRUM DISORDER 
ASD is a collection neurodevelopmental disorders presenting with a wide range of 
symptoms, each with varying severity that can be observed in patients. Due to the large 
variety of symptoms, patients are diagnosed on three core behaviors: impaired social 
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interaction, communication and language deficits, and repetitive behaviors. In recent years, 
clinicians have begun to consider social and communication abnormalities under the same 
umbrella7. 
 The prevalence of ASD has been growing since it was first recognized as a unifiable 
clinical disorder. As per the most recent data from the surveillance year of 2014, 1 in 59 
children were diagnosed with ASD, an increase from 1 in 125 just 10 years prior8. This 
increasing rate of occurrence cannot solely be attributed to an improvement in early 
detection methods or a more established set of diagnosis attributes. Nonetheless, 
identification of the underlying cause of ASD has not yet been deduced. A plethora of 
research on the subject has led to the consensus that a combination of genetic and 
environmental risk factors likely contributes to the underlying pathology of the disorder9. 
 Over 1,000 genes have been implicated through extensive peer reviewed studies. 
The Simons Foundation Autism Research Initiative (SFARI) curates this data and presents 
the genes on a ranked scale of 1-5. The scale indicates the strength of the evidence linking 
the gene to ASD, with 1 being the strongest. The ranking also indicates if the gene is linked 
to a co-morbid syndrome, since syndromic genes can be more confidently linked to ASD. 
Additionally, the genes discovered with a promising link have led to 1,638 mouse lines and 
361 rat lines, among others, which are assessed on the same core behaviors that the disorder 
is diagnosed upon in humans10. Despite this extensive research though, genetics cannot 
wholly account for the pathology of ASD.  
 Roughly 85% of cases of ASD are idiopathic and cannot be explained by genetics 
alone11. It is thought, therefore, that environmental risk factors play a role in explaining the 
remaining cases. While several environmental factors are confirmed to have a role in ASD, 
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a list of potential risk factors with links to some ASD behavioral phenotypes warrant 
further investigation12. Studies into risk factors are often contradictory; positive 
correlations between risk factors and ASD are highly dependent on the biological pathway 
assessed and the time of exposure during development. Many of the proposed risk factors 
are common, such as lead and pesticides12, and there is concern regarding the 
inconsistencies in methods used to determine if environmental toxins are risk factors for 
ASD13. 
 To accurately assess the contribution of risk factors to ASD, a robust method for 
evaluating ASD models must be considered. Currently, behavioral tests govern the 
diagnosis of ASD in animal models. This is largely due to the wide variety of behavioral, 
physical, and molecular presentations. In looking for a commonality to study, arguably the 
most reproducible biomarker is hyperserotonemia, or high blood serotonin, which is 
present in about one-third of individuals with ASD14. While serotonin concentrations in 
the body are easy to measure, analysis of the central nervous system is notoriously difficult. 
This difficulty means that little is known about the interaction between serotonin in the 
peripheral and central nervous systems.  
A variety of factors make serotonin an ideal target for studying ASD. The 
neurotransmitter is thought to play a role in regulating a range of behaviors which are 
commonly altered in ASD6, 15. Serotonin’s role in brain development, specifically as a 
growth factor during embryogenesis and in brain structure development16, suggest that 
alterations in the neurotransmitter could contribute to developmental disorders such as 
ASD. Recently, research has found serotonin plays a role in gene regulation in neurons17, 
suggesting that any changes in the regulation of serotonin, such as from environmental 
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factors, could alter gene expression. Finally, and perhaps the most convincing argument 
that serotonin plays a role in ASD, is that selective serotonin reuptake inhibitors (SSRIs) 
(a class of antidepressants) are the most commonly prescribed psychoactive drug for 
treating ASD behaviors18. In endeavoring to find a commonality among ASD models, a 
compelling argument for serotonin as the missing link exists. 
1.3 MEASURING SEROTONIN 
Measuring serotonin in the brain is very difficult for a variety of reasons, including 
the fragile nature of the brain, the similarities between serotonin and other monoamine 
neurotransmitters, the low levels at which neurotransmitters are present, and the rapid time 
scale during which neurotransmission takes place. The most commonly used technique for 
measuring serotonin in vivo is microdialysis, however this method typically provides 
information on the basal concentrations of serotonin every 20 minutes, though some 
improvements have resulted in slightly faster time resolution19. To understand the 
functionality of the serotonin circuit and the evaluate the processes which regulate 
serotonin neurotransmission, fast-scan cyclic voltammetry (FSCV) is a landmark 
technique.   
 
 
Figure 1.1: Fast-Scan Cyclic Voltammetry. Panel A of Figure 1.1 illustrates a 
representative color plot of serotonin, with the waveform shown on the left side. 
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The horizontal dotted line corresponds to the IT curve in Panel B which has been 
converted to concentration. The vertical dotted line corresponds to the inset CV 
in Panel B, which confirms the presence of serotonin with the oxidation peak at 
~0.7 V.   
 
FSCV for serotonin utilizes carbon fiber microelectrodes (CFMs) of 7 µm in 
diameter and 150 µm in length. The CFMs are electroplated with Nafion, a cation exchange 
polymer which serves to exclude species that poison CFMs. A serotonin specific 
waveform, shown in Figure 1.1, is applied to the electrode surface at a scan rate of 1000 
V/s to selectively oxidize and reduce serotonin20. A stimulation electrode applies a brief 
electrical stimulation to evoke the release of serotonin in vivo. During this time, files are 
collected at 10 Hz, allowing observation of the release of serotonin into the extracellular 
space and subsequent reuptake back into the cells, as shown in Figure 1.1 current vs. time 
(IT) trace. Confirmation that the analyte is serotonin comes from the characteristic 
oxidation peak at 0.7 V found on the current vs voltage (CV) plot. The current from this 
oxidation can then be converted to concentration, allowing for the quantification of 
serotonin. Mathematical modeling can be utilized to glean information from the IT curve 
regarding the autoreceptors and transporters which regulate serotonin transmission21. 
While FSCV provides a wealth of useful information, the method is limited because it 
relies on background subtraction, meaning that ambient or basal levels cannot be known. 
To alleviate this restraint, the method was adapted to measure ambient concentrations of 
serotonin using fast-scan controlled adsorption voltammetry (FSCAV)22.  
FSCAV uses the same waveform as FSCV but applied at a higher frequency. 
FSCAV has three distinct steps, as shown in Figure 1.2. The first of these steps is 
application of the waveform at 100 Hz to minimize adsorption on the surface of the 
electrode, the second is a controlled adsorption step which holds a constant potential at the 
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electrode surface until maximum serotonin adsorption has been achieved. Finally, the 
waveform is reapplied and everything at the surface of the electrode is stripped, and all 
adsorbed serotonin is oxidized. The first CV with the characteristic serotonin oxidation 
peak is extracted, as shown in Figure 1.2 and the peak is integrated to yield the charge. 
Calibrations of each electrode inform upon the relationship between charge and 
concentration to allow in vivo values to be converted to concentration of serotonin. 
Combining this ambient serotonin concentration with the evoked release of serotonin 
provides a multi-faceted platform from which to evaluate serotonin neurotransmission. The 
combination of these techniques proves to be very advantageous for assessing the 
functionality of the serotonin system and detect any variations which may exist during 
disease states.   
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Figure 1.2: Fast-Scan Controlled Adsorption 
Voltammetry. Panel A of Figure 1.2 illustrates a 
representative color plot of serotonin, with a portion of 
this color plot zoomed in on for Panel B presenting the 
application of the waveform during the three stages of 
FSCAV. Panel C presents an unfolded CV with the area 
under the curve of the serotonin peak integrated to yield 
the charge needed to convert to ambient serotonin 
concentration.   
 
FSCV and FSCAV were established in the brain regions, substantia nigra pars 
reticulata (SNr) and in the CA2 region of the hippocampus22, 23. However, to best evaluate 
serotonin in ASD a region with a more pronounced associated to the disorder should be 
studied. This brain area should ideally also have a high density of serotonin axons for 
measurement with FSCV and FSCAV.  The prefrontal cortex (PFC) fits these criteria and 
is the most commonly documented region to have an overgrowth of neurons in ASD 
patients24. The PFC also mediates communication, cognitive development, and higher-
order social and emotional behavior25, all of which are heavily implicated in the core 
behavioral symptoms of ASD and make the PFC an ideal target for evaluating serotonin 
with FSCV.  
1.4 SCOPE OF DISSERTATION 
 
This dissertation will focus on establishing and modeling serotonin neurochemistry 
in the prefrontal cortex with FSCV and FSCAV. The unique serotonin signals found in this 
region will be compared to those in previously established regions, including the SNr and 
the CA2. These methods will be applied in well accepted genetic models of ASD. Finally, 
a perinatal lead exposure will be used to assess lead as a risk factor for ASD with behavioral 
and neurochemical serotonin analysis.  
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CHAPTER 2: 
VOLTAMMETRIC EVIDENCE FOR DISCRETE SEROTONIN 
CIRCUITS, LINKED TO SPECIFIC REUPTAKE DOMAINS, IN THE 































1 West, A., Best, J., Abdalla, A., Nijhout, F., Reed, M., Hashemi, P.; Neurochemistry 
International. 2019. 123:50-58.   
Reprinted here with permission of publisher.
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2.1 INTRODUCTION 
The medial prefrontal cortex (mPFC) has garnered substantial interest in recent 
times amongst a diverse group of experts 26-28. Cutting-edge research has centered on the 
role of the mPFC in differentiating memories 27 and suppressing reward-seeking behavior 
28 via projections to other brain regions. Recent work has identified a key factor in the 
mPFC which may be imperative to treating addiction without the potential for abuse 26. 
These studies, among others, highlight the many functions of the mPFC and the importance 
they play in a variety of contexts. 
The role of the mPFC in modulating behavior is widely encompassing, with only a 
few functions mentioned above.  As such, changes during development, including stress, 
drugs or social interactions, can affect the organization and function of the mPFC possibly 
leading to behavioral impairment 25. To this end, our laboratory is interested in 
investigating the mPFC in the context of developmental disorders. Our specific interest is 
to understand how the chemistry in this area underlies the behavioral phenotypes of 
pathologies such as autism spectrum disorder (ASD). Since serotonin plays significant 
roles in early brain development 29 and the mPFC is densely innervated with this 
messenger’s neurons 30, we find it meritorious to focus our chemical studies on serotonin. 
Serotonin chemistry in the periphery is impaired during ASD 31 however, there is currently 
no consensus on how or if the brain’s serotonin chemistry, specifically in the mPFC, is 
altered during ASD. For example, human positron emission studies and animal 
autoradiographic studies are contradictory in their reports of serotonin transporter (SERT) 
density and binding capacity, with some reporting decreased SERT binding compared to 
controls, yet others showing no change in SERT density 32, 33 in ASD cases and models. 
These studies are then necessarily at odds with other animal-only ASD models that show 
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region-dependent abnormalities in the density of serotonin neurons 34, reduced SERT 
binding 35 and reduced excitatory transmission 36.  
Given the uncertainties outlined above, here we seek to better define serotonin 
chemistry in the mPFC by applying cutting edge analytical methods, fast-scan cyclic 
voltammetry (FSCV) and fast-scan controlled adsorption voltammetry (FSCAV), for real-
time in vivo serotonin analysis in the mPFC. The small size (~7 µm) of the carbon fiber 
microelectrode (CFM) and excellent selectivity and sensitivity of these techniques allows 
for sub-second measurements of stimulated serotonin release and reuptake as well as rapid 
(<1 minute) ambient level measurements. 
Our previous work with FSCV revealed a single phase evoked serotonin response 
in the substantia nigra, pars reticulata (SNr) upon medial forebrain bundle (MFB) 
stimulation 21. We noted a curious phenomenon in the reuptake profile of serotonin in this 
region. In some cases, the response would be cleared “fast” (<10 seconds) with a single 
reuptake curve. In other instances, the response decayed with a “slow” (>20 seconds) 
profile but in most cases, a combination of ‘fast’ and ‘slow’ clearance profiles resulted in 
a ‘hybrid’ reuptake. The ‘fast’ and ‘slow’ responses were identified as two distinct 
clearance mechanisms: Uptake 1, mediated by the serotonin transporters (SERTs), and 
Uptake 2, mediated by other monoamine transporters (dopamine transporters (DATs), 
norepinephrine transporters (NETs), and organic cation transporters (OCTs)). These 
mechanisms had previously been identified and while Uptake 2 was defined as high 
capacity, low affinity uptake, DATs and NETs can be included since each has multiple 
types of transporters that band together to simultaneously remove serotonin 5, 37. We 
mathematically modeled our experimental curves and reported two sets of Michaelis-
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Menten parameters corresponding to Uptake 1 (high affinity, low efficiency) and Uptake 
2 (low affinity, high efficiency).  
Here in the mPFC, we found similar single phase evoked responses with a hybrid 
clearance profile. Additionally, for the first time, we observed two evoked responses to a 
single MFB stimulation; of particular significance, the two phases had different reuptake 
profiles. We found a strong correlation between the occurrence of single or dual responses 
and the position of the CFM within the mPFC layers. Additionally, the magnitude of the 
second phase in the dual phase response was dependent on the position of the stimulating 
electrode. These findings allowed us to hypothesize that there are distinct subsets of 
serotonin axons traversing the MFB, that terminate in discrete domains with specific 
reuptake profiles. We utilized pharmacology, histology and an elaboration of our prior 
model in the SNr to test this hypothesis. We subsequently showed that a comprehensive 
and highly organized cellular network underlies the control of serotonin chemistry in the 
mPFC. Our findings will, in the future, serve as a base chemical model to study serotonin 
dysfunction in models of ASD. 
2.2 METHODS 
2.2.1 ANIMALS AND SURGICAL PROCEDURES 
All procedures described herein are in agreement with The Guide for the Care and 
Use of Laboratory Animals and approved by the Institutional Animal Care and Use 
Committee (IACUC) of the University of South Carolina (USC). Male C57BL/6 mice 
(Jackson Laboratory, Bar Harbor, ME) between 20-30 grams were used for all stereotaxic 
surgical experiments. Mice were housed in the USC animal care facility under a 12-hour 
light/dark cycle with access to food and water ad libitum. Experiments were performed 
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during the light phase. Mice were injected with a 25% urethane solution (dissolved in 0.9% 
saline, Hospira, Lake Forest, IL, USA) intraperitoneally (i.p.) and maintained on a heating 
pad (Braintree Scientific, Braintree, MA, USA) at 37°C. Fully anesthetized mice were 
placed in a stereotaxic frame (David Kopf Instruments, Tujunga, CA, USA) for intracranial 
surgery. Stereotaxic coordinates were each taken in reference to Bregma 38. A Nafion 
coated carbon fiber microelectrode was lowered into the medial prefrontal cortex (AP: 
+1.70, ML: -0.20, DV: -2.20 to -2.90) and a stainless-steel stimulating electrode (SE) 
placed in the medial forebrain bundle (MFB) (AP: -1.58, ML: -1.00, DV: -4.80). A 
Ag/AgCl reference electrode was placed in the contralateral hemisphere (AP: -3.15, ML: 
+1.70). Placement of the working electrode (WE) was adjusted in the dorsal/ventral plane 
until the desired serotonin signal was observed. 
2.2.2 VOLTAMMETRY 
2.2.2.1 CARBON-FIBER MICROELECTRODES (CFMS) 
CFMs were fabricated in house using ~7 µm diameter carbon fibers (Goodfellow 
Corporation, PA, USA). The carbon fibers were aspirated into glass capillaries (ED 0.6 
mm, ID 0.4 mm; A-M systems, Inc., Sequim, WA, USA) and pulled via a vertical 
micropipette puller (Narishige Group, Tokyo, Japan). Under an optical microscope, carbon 
fibers were cut to 150 µm. An electrical connection was forged between the carbon fiber 
and connection wire using silver paint. CFMs were then electroplated with nafion 23. 
2.2.2.2 FAST-SCAN CYCLIC VOLTAMMETRY  
The serotonin waveform was generated using a PCIe-6341 DAC/ADC (National 
Instruments, TX, USA) card. The working electrode was scanned at 1000 V s-1 from 0.2 V 
to 1.0 V, down to -0.1 V then back to 0.2 V and cycled at 10 Hz 20. Bi-polar electrical 
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stimulations induced serotonin release (60 Hz, 120 pulses, 350 µA, 4 ms pulse width), 
delivered through a linear constant current stimulus isolator. A CHEM-CLAMP 
potentiostat (Dagan Corporation, MN, USA) measured current. Potentials were measured 
against a Ag/AgCl reference electrode. A predetermined calibration factor of 49.5 ± 10.2 
nA μM− 1 was used to convert current to concentration 23. 
2.2.2.3 FAST-SCAN CONTROLLED ADSORPTION VOLTAMMETRY  
FSCAV was performed using a CMOS precision analog switch, ADG419 (Analog 
Devices) to control the application of the computer-generated waveform to the electrode. 
The logic was controlled programmatically with a series of ramps. The waveform (0.2–1.0 
V to −0.1–0.2 V, scan rate = 1000 V s-1) was applied at a frequency of 100 Hz for 2 seconds, 
followed by holding at a constant potential (0.2 V) for 10 seconds, and finally followed by 
the recommencement of the waveform for a total file collection time of 30 seconds. 22. 
2.2.2.4 STIMULATION LOCATION EXPERIMENTS 
Experiments were carried out to explore the contribution of stimulations along the 
MFB to the double peak signal amplitude. For these experiments, control files were 
collected, and the stimulation electrode was then removed from the brain and placed either 
anterior or posterior to the original placement before being lowered into the brain again. 
Control files were collected at the secondary SE placement and the procedure was repeated 
a third time with the SE moved opposite its initial placement (either anterior or posterior). 





2.2.2.5 ANALYSIS AND STATISTICS 
Custom software (WCCV 3.0, Knowmad Technologies LLC, Tucson, AZ, USA) 
was used for data collection, processing, and analysis. Data was background subtracted and 
filtered at zero-phase using a fourth order Butterworth 5 kHz low pass filter. FSCV yields 
cyclic voltammograms (CVs) which can be used both qualitatively and quantitatively. CVs 
are stacked in time to produce a 2-D color plot which allows for extrapolation of current 
vs. time (IT) plots as well as CVs. IT plots were written as text files and imported to Excel 
where they were averaged across each time point and converted to concentration using a 
predetermined calibration factor (vide supra). An average concentration vs. time trace is 
generated from this process and the standard error of the mean, taken across each time 
point, is added to the plot.   
FSCAV data was processed and electrodes calibrated as previously described 22.  
2.2.2.6 PHARMACOLOGY 
Mice were administered a bolus intraperitoneal (i.p.) injection of 10 mg kg-1 
escitalopram (ESCIT) (Sigma-Aldrich, St. Louis, MO) during the experiment. Files were 
collected for up to two hours following injection. 
2.2.2.7 EXCLUSION CRITERIA 
If the cyclic voltammograms (CVs) collected with FSCV and FSCAV did not 
match the characteristics of serotonin CVs collected in vitro, the mice were excluded from 
this study. Mice that died before the end of the collection time were excluded. Mice were 
also excluded if the electrode was found not be located in the MFB after histology. All 




Following data collection, a large potential (13 V for 90 seconds) was passed 
through the working electrode to lesion the brain. Mouse brains were harvested, following 
euthanasia, and stored in 4% paraformaldehyde until ready for slice analysis. Brains were 
transferred to 20% sucrose solution 48 hours prior to sectioning. Each brain was sectioned 
(30 µm) using a cryotome and sections were analyzed for working and stimulating 
electrode placement. Electrode placements were verified, and mPFC subsection location 
of the CFM determined based on the Allen Mouse Brain Atlas (Allen, 2004). 
2.2.4 MODELING 
Our model for this work is an elaboration of a prior model 21, with addition of two 
domains, which are two distinct types of termini clusters. Domain 1, Dmn1, is subject to 
both Uptake 1 and 2 and receives input from Population 1. Domain 2, Dmn2, subject only 
to Uptake 1 and receives input from Population 2. Let x be a variable that goes from Dmn2 
(x =0) to Dmn1, where we expect that L (maximum distance between  Dmn1  to Dmn2, as 
estimated from the maximum distance across characteristically similar layers) (Allen 
Mouse Brain Atlas, 2004) will be of the order of magnitude of 500 µm.  
As depicted in Figure 2.1, Dmn2 is the region 0 < x < a and Dmn1 is the region b < 
x < L where x is a distance variable indicating the position of interest.  Let u(t,x) be the 
extracellular concentration of serotonin at x at time, t.  Then u(t,x) satisfies the partial 
differential equation (1): 
𝜕𝑢(𝑡,𝑥)
𝜕𝑡
= 𝐼𝑛𝑝𝑢𝑡 (𝑡, 𝑥) −  𝑈𝑝𝑡𝑎𝑘𝑒 (𝑡, 𝑥) + k ∙
𝜕2𝑢(𝑡,𝑥)
𝜕2𝑥
   (1) 










Figure 2.1: Representation of the Mathematical Model. Panel A of 
Figure 2.1 shows a geometric sketch of a physiological hypothesis. 
Population 1 provides input to Dmn1, located between x = b and x = 
L. Dmn1 has both Uptake 1 and Uptake 2. Population 2 provides input 
to Dmn2, located between x = 0 and x = a. Dmn2 has Uptake 1. In the 
middle region (between x = a and x = b), there is no input and no 
reuptake but extracellular serotonin is free to diffuse. The response 
(blue) in Panel B shows the time course of extracellular serotonin if 
only population 1 were stimulated. The response (red) in Panel B 
shows the time course of extracellular serotonin if only population 2 
were stimulated. Experimentally, sole stimulation of population 2 has 
not been observed. 
 
Where k is the diffusion coefficient of serotonin in the extracellular space.  The 
initial condition (2) states that at time = 0 the system is at steady state and the extracellular 
concentration of serotonin is equal to 60 nM at all x (estimated from prior models and 
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experimental data Appendix Figure A.4) 22. The boundary condition (3) guarantees that 
serotonin cannot diffuse out of the interval [0,L]. 
Input(t,x) is constant at the steady state level until t = 5 seconds, which is the start 
of MFB stimulation. For a few seconds after t = 5, impulses arriving from populations 1 
and 2 increase the serotonin concentrations in Dmn1 and Dmn2 creating FSCV peaks. After 
that the peak amplitudes dip below basal level until 30 seconds because of prolonged 
autoreceptor effects discussed previously 21. The strength of the inputs to Dmn1 and Dmn2 
depend on the position and strength of the MFB stimulation and are varied in our simulation 
experiments. There is no input between x = a and x = b. 
In Dmn1, Uptake(t,x) is both by Uptake 1 and Uptake 2. Uptake 1 has a Michaelis-
Menten profile with Vmax1 = 19.25 nM s
-1 and KM1 = 5 nM. Uptake 2 also follows Michaelis-
Menten kinetics with parameters Vmax2 = 780 nM s
-1 and KM2 = 170 nM. These parameters 
are almost identical to those we previously established in the SNr 21. The constraints of this 
model include that Dmn2 is subject to Uptake 1, that Uptake 2 operates only at 
concentrations above 75 nM, and that there is no uptake between x = a and x = b. 
The question that we investigate in the simulations in this paper is what will happen 
in the extracellular space if serotonin can diffuse from type 2 domains (Dmn2), to the 
electrode surface, which is enveloped by type 1 domains (Dmn1). In all of our simulations 
we assume Dmn1 are ubiquitous around the electrode. The parameter r, s1, and s2, are 
proportional to serotonin release in Dmn1 and Dmn2, respectively. Model simulations were 
performed using MatLab R2017b (MathWorks, Natick, MA, USA) using ODE solver 
ode23s implemented on an iMAC with operating system OS X version 10.12.6. 
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2.3 RESULTS AND DISCUSSION 
2.3.1 TWO SEROTONIN RELEASE EVENTS IN RESPONSE TO A SINGLE 
STIMULATION 
The MFB was stimulated and serotonin was detected in the mPFC at an implanted 
CFM. Examples of serotonin release are shown in the color plots in Figure 2.2 (vide supra 
for color plot interpretation). This kind of stimulation - measurement method is well 
established in dopamine voltammetry; for example, dopamine release is induced in the 
nucleus accumbens upon MFB stimulation 39. It is generally well accepted in the 
voltammetry community that MFB stimulated dopamine release, which is abolished via 
lidocaine-induced cell body inactivation, is antidromic 40. We believe that this principle 
applies to MFB stimulated serotonin release in the mPFC.  
Figure 2.2A shows the average serotonin response in the mPFC with error bars 
signifying standard error of the mean for responses averaged between animals. This 
average response is tallied as a function of two distinct response types. Specifically, in 
some experiments, we recorded a single evoked serotonin peak with primarily Uptake 2 
clearance. However, an equal amount of times we observed a double peak, or dual event, 
in response to the stimulation. The second peak appeared to be delayed and the amplitude 
varied with respect to the first. The appearance of these dual responses varied substantially, 
and representative examples of the five most common types we observed are shown in 
Figure 2.2B. The CVs of both peaks, shown in the inset, clearly identified each release 
event as serotonin with an oxidation peak around 0.7 V. Capacitive currents were observed 
on the color plots and CVs at the switching potentials in Figure 2.2B, though they did not 




Figure 2.2: Serotonin Responses in the mPFC. The average response of all signals recorded 
in the mPFC can be seen in (A) with error bars showing SEM. The variety of these signals 
can be seen in (B) with color plots, concentration vs. time traces, and inset CVs 
corresponding to the peaks identified from the color plot. The traditional single peak is 
shown in (i.) along with the variety of double peaks seen in (ii.-vi.). Inset CVs confirm that 
each peak is serotonin by the oxidation peak at ~0.7 V. The correlation between the 
individual signals and their experiment number (seen in Table 2.1) is as follows: i.-17, ii.-
3, iii.-2, iv.-7, v.-9, vi.-5. 
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To the best of our knowledge, this is the first time that biphasic responses have been 
observed with serotonin. Dopamine has been previously observed, with FSCV, to exhibit 
a variety of profiles depending on measurement location, though the reasoning for these 
responses cannot wholly be applied to this instance for serotonin 42.  
While several hypotheses were considered for this biphasic phenomenon, including 
mobilization of different vesicular pools and second messenger effects, we believe that the 
data are best explained via a combination of two theories. First, parallel projection systems 
have previously been postulated to underpin dopamine circuitry from the ventral tegmental 
area 43. Likewise, parallel serotonin pathways from the dorsal and median raphe nuclei 
project to the mPFC 44, 45. Second, biochemically distinct compartments form the basis of 
the striosome-matrix hypothesis 46-48. Thus, here we hypothesize two different, parallel 
populations of serotonin axons in the MFB that terminate in different biochemical 
compartments (not to be confused with mPFC layers), which here we term domains, Dmn1 
and Dmn2. Dmn1 receives input from population 1 and clearance occurs via both Uptake 1 
and Uptake 2. Dmn2 receives input from population 2 and the serotonin released here is 
cleared via Uptake 1. An illustration of this hypothesis, with two scenarios illustrating the 
CFM location either in layers 1-3 or in layers 5-6, can be found in Figure 2.3. The prospect 
of Uptake 2 clearing serotonin is substantiated as DATs, NETs, and OCTs have been found 
in the mPFC. While rodent studies have shown a higher expression of SERTs compared to 
DATs and NETs in the mPFC 49, their high efficiency allows them to suitably clear 
serotonin. OCTs have been found with some abundance in the mPFC 50 but information 




Figure 2.3: Theory Schematic. Population 1 (blue) has 
input to all layers and terminates in Dmn1 with Uptake 
1 (SERTs, green triangles) and Uptake 2 (non-SERTs, 
yellow squares) transporters. Population 2 (red) has 
input primarily to layers 5 and 6 and terminates in 
Dmn2 where Uptake 1 dominates. The time delay of the 
second peak is due to diffusion, since Dmn2 is more 
sparse, thus farther from the CFM. This phenomenon 
also explains why the second peak is only observed in 
layers 1-3 after administering ESCIT (see Figure 2.5); 
where amplitude of serotonin released in Dmn2 is now 
high enough to be measured. 
 
Our experimental data (vida infra) suggests that Dmn2 occurs sparsely across layers 
and that Dmn1 is ubiquitous. The sparse innervation of Dmn2 is such that we believe that 
our electrode is never close enough to detect peaks from Dmn2 first, but the ubiquitous 
nature of Dmn1 makes our electrode constantly consistently surrounded by this domain. 
Our hypothesis is that the second peak is caused by the diffusion of serotonin from Dmn2, 
via activation of population 2, to the electrode surface. We now explore this notion in more 
detail. 
Figure 2.4 shows data from a representative experiment where a dual response is 
observed pre (blue trace) and post (red trace) 10 mg kg-1 ESCIT administration. Pre-drug, 
the extracellular serotonin rises rapidly after the stimulation followed by a rapid, Uptake 2 
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mediated, decline. At about t = 11 seconds the curve begins to rise again because of 
diffusion of serotonin from Dmn2 to the CFM. In this example the initial reuptake profile 
of the second peak is primarily mediated by Uptake 2 as serotonin from Dmn2 has diffused 
to the electrode surface which is surrounded by Dmn1 and the high concentrations of 
serotonin have activated Dmn1 Uptake 2 transporters. Once the concentration falls below 
a certain threshold, Uptake 2 ceases and Uptake 1 dominates. Post ESCIT, the first peak is 
not largely affected because ESCIT does not significantly target Uptake 2 transporters 51. 
The second peak, conversely, increases in amplitude and the decay is significantly slowed, 
because clearance here is mostly mediated by Uptake 1 (SERTs). This response to ESCIT 
was a consistent trend seen across the dual response signals obtained. An additional 
representative experiment with these conditions can be found in the Appendix (Figure A.1). 
 
 
Figure 2.4: A Double Peak pharmacological experiment. A representative 
response (experiment 18) is shown before (blue) and after (red) i.p. 
administration of 10 mg kg-1 ESCIT. Both curves show a biphasic response. 
Our hypothesis of diffusion from Dmn2 to Dmn1 explains the differences 
between the curves.  
 
 These results confirm that the two individual peaks are selectively associated with 
different uptake mechanisms. This uptake specificity exists regardless of whether a second 
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peak is observed or not. Above we hypothesized that the two peaks result from activation 
of separate populations and explore this in more detail in the following sections. 
 2.3.2 SINGLE OR DUAL EVOKED RESPONSE ARE DEPENDENT ON SUB-
REGION LAYERS 
In defining the origin of the two evoked serotonin peaks, we first explored the 
correlation of the position of the CFM in the mPFC tapestry to the prevalence of single vs. 
double peaks. Following data collection, a large potential was applied to the working 
electrode, which we previously found successfully created an identifying lesion in the brain 
tissue (otherwise undetectable due to the miniature dimensions of the CFM). The lesions 
were categorized on the sub region (prelimbic, infralimbic, and anterior cingulate cortex) 
and layer (1-6) of the mPFC. We found no trend between sub regions, but single vs. double 
peaks were distinctly dependent on layer. Table 2.1 correlates the signal type (single vs. 
double) with the sub-region and layer in which the CFM made measurements. Visual 
representation of the histology can be found in the Appendix (Figure A.2).  
Double peaks were consistently observed in layers 5-6, while single peaks were 
seen only in layers 1-3. This trend was consistent across all subregions of the mPFC. While 
layers are traditionally defined by the synaptic density 52, the data shown here supports the 
theory that the layers may also define the topographical limits of functionally different 
serotonin neurons. In support of this, morphological differences between cortex 
varicosities have been identified 53. These different varicosities can be directly associated 
with specific projections from the dorsal and medial raphe which have been shown to 
terminate in a layer dependent manner 44, 45, 53. In addition, there is genetic 54 and 
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electrophysiological 55 evidence for functionally different serotonin neurons in the frontal 
cortex. 










1 Two Anterior Cingulate 5 
2 Two Prelimbic 5 
3 Two Anterior Cingulate 5 
4 Two Anterior Cingulate 5 
5 Two Anterior Cingulate 6a 
6 One Anterior Cingulate 2/3 
7 Two Prelimbic 5 
8 One Infralimbic 2/3 
9 Two Anterior Cingulate 5 
10 One Anterior Cingulate 2/3 
11 One Infralimbic 1 
12 One Infralimbic 1 
13 One Infralimbic 1 
14 Two Anterior Cingulate 5 
15 One Prelimbic 2/3 
16 One Anterior Cingulate 1 
17 One Infralimbic 1 
18 Two Infralimbic 5 
19 One Anterior Cingulate 2/3 
20 Two Prelimbic 5 
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An interesting phenomenon was observed following administration of ESCIT in 
experiments where only single peaks were observed; a second peak could emerge after 
ESCIT.  Figure 2.5 shows a representative experiment where single evoked events were 
measured before (control, blue) and 40-60 minutes after (red) ESCIT. Histology confirmed 
that the CFM was located in layer 1-3, as above for single peaks. An additional 




Figure 2.5: A Single Peak Pharmacological Experiment. 
The [5-HT] vs time traces are shown for a representative 
(experiment 15) single peak serotonin response before 
(blue) and 60 minutes after (red) 10 mg kg-1 ESCIT 
administration. Histology confirmed that the CFM was in 
layers 1-3. 
 
 The experiments listed in Table 2.1 revealed that the occurrence of single or dual 
evoked events are dependent on the layer in which the CFM is located. Figure 2.5 
experiments indicated layer 1-3 have the potential for the second peak, but that prior to 
ESCIT the amplitude is too low to be detected. The capacity for a second peak provides 
support for the presence of Dmn2 in layers 1-3, though much more sparse than in layers 5-
6, resulting in an amplitude too low to be detected without pharmacological intervention.  
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We observed another phenomenon related to the dual response. In different animals there 
was a large variance in the ratio of the amplitude of the second to first serotonin peak even 
when the CFM was in the same layer and sub region, pointing towards an important role 
for the stimulation location. We next investigated this notion. 
2.3.3 SECOND PEAK AMPLITUDE IS HEAVILY DEPENDENT ON MFB 
STIMULATION 
To further define the origin of the two evoked serotonin peaks, we test the 
hypothesis that the two evoked serotonin events occur via stimulation of separate axonal 
populations, traversing the MFB. We found that stimulating different locations along the 
MFB, in the AP axes, changed evoked serotonin amplitude, with the most significant effect 
on the second peak. We postulate that these stimulation electrode placements have less 
effect on the first peak because axonal population 1 must be more consistently located 
along the MFB tract that we probed.  
Figure 2.6A depicts three double peak signals obtained in one animal. Each signal 
was collected by stimulating a different location along the MFB moving anterior (i) to 
posterior (iii). The second peak amplitude increases with the anterior placement of the SE 
and decreases posterior. In the third signal (iii), and most posterior SE placement, the 
second peak is almost completely eliminated. In Figure 2.6B the experiment was repeated 
when a single peak was observed, and movement of the SE did not cause a double peak to 
appear. This allows us to conclude that while the stimulation along the MFB controls the 
amplitude of the second peak, the presence of a single or double peak remains wholly 
dependent on the CFM placement within the mPFC layers.  





Figure 2.6: Investigating the Effects of Stimulation Location. The left panel 
(A) shows a serotonin double peak response in a single animal (experiment 
9). The right side (B) shows a serotonin single peak response in a single 
animal (experiment 11). In each experiment, control files were collected 
with three different SE placements (i.-iii.) while the WE remained in the 
same place. The SE was removed from the brain and reinserted twice, 
anterior (i.) and posterior (iii.) to the original (ii.) placement. 
  
2.3.4 MODELING TWO DISCRETE AXONAL POPULATIONS THAT TERMINATE 
ONTO SPECIFIC TRANSPORTER DOMAINS  
Figure 2.2B shows five different experimental response curves measured in layers 
5-6, and one response measured in layers 1-3 of the mPFC. Our fundamental hypothesis is 
that there are two types of domains in layers 5 and 6: Dmn1 is innervated by population 1 
of axons from the MFB and once released into this domain, serotonin is reuptaken by 
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Uptake 1 and 2 transporters. Dmn2 is innervated by population 2 axons and once serotonin 
is released into this domain, it is uptaken by Uptake 1 transporters. We experimentally 
demonstrated that Dmn1 is ubiquitous and Dmn2 occurs more sparsely. Therefore, we 
assumed that the CFM always measures serotonin released from Dmn1. The potential for 
the CFM to measure serotonin released from Dmn2 depends on several factors including: 
input to population 2, the diffusion length L, and coefficient k. As the serotonin released 
from Dmn2 diffuses through the extracellular tissue it is reuptaken by the transporters of 
surrounding domains, thus its reuptake profile is heavily dependent on the extracellular 
serotonin concentrations. In the Materials and Methods Section 2.2.4, we formulated a 
mathematical model based on these hypotheses. Our mathematical model fails if serotonin 
from Dmn2 was either cleared exclusively cleared by Uptake 2 or initially cleared by 
Uptake 2 and the subsequently cleared by Uptake 1.  
Our model represents a highly complex physiological system and the intent is not 
to exactly match the experimental curves in Figure 2.2B. Rather, the purpose is to show, 
using the model, that by varying s1 and s2, the strengths of the stimulation from populations 
1 and 2, respectively, the diffusion length L and coefficient 𝑘, and the basal extracellular 
serotonin, that we can obtain the variety of behaviors seen in the experimental curves in 
Figure 2.2. We next discuss the response and model curves (i)-(vi) individually. Of note: 
although the aspect ratios of the curves are the same, the scale of the y-axis varies in both 





Figure 2.7: Model Simulations. Panels i.-vi. show the extracellular serotonin 
response with different choices of parameters. s1 and s2 represent the strength of 
the neural inputs to Domains 1 and 2, respectively. In Panel (i) there is no 
diffusion, so the response only represents serotonin released from Dmn1. In 
Panels (ii), (iii), (iv), (v), and (vi) the diffusion coefficient is the same, k=0.3 
(nM)2 s-1. In each panel the approximate basal level of extracellular serotonin is 
indicated. We have shown, using FSCAV, that basal serotonin levels in the 
mPFC vary over a range of 50-75 nM (see Appendix Figure A.4). In Panels (iii), 
(v), and (vi) the diffusion length (L) from Dmn2 to Dmn1 is reduced by 33%. 
These simulations can be compared with experimental curves in Figure 2.2B.  
 
Response (i).  The single peak simulated here arose from stimulation of population 
1 (s1=0.5), uptaken rapidly, indicating mainly Uptake 2 mediated transport 
21. To 
fit this peak the following parameters were implemented: diffusion coefficient 𝑘 = 
0, indicating no diffusion took place from Dmn2 to Dmn1 where the CFM is located. 
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The basal level of serotonin in the extracellular space was assumed to be in the 
higher range, making Uptake 2 operational. Thus Uptake 2 quickly brought the 
released serotonin back down to baseline. The curve then descended below baseline 
as a result of the autoreceptor effect previously discussed 21. 
Response (ii). For this simulation, population 2 was stimulated in addition to 
population 1 resulting in diffusion of serotonin from Dmn2 to the electrode surface, 
resulting in two peaks. The first peak descended quickly because the extracellular 
serotonin is within the range which Uptake 2 operated. The second peak was 
reuptaken more slowly by the Uptake 1 transporters as the extracellular serotonin 
descended below the range of Uptake 2, in addition to the fact that serotonin 
continued diffusing from Dmn2.  
Response (iii). This resembled a typical hybrid response previously observed 21, 
with the exception that a second peak shortly followed the first. To simulate this 
response, the stimulation of population 1 was s1 = 0.6, and that of population 2 was 
s2 = 1. The basal level of serotonin was in the middle range. The model then 
produced a hybrid response with a slight second peak that occurred close to the first 
peak as the diffusion length between the two domains was reduced by 33%. 
Response (iv). The simulation shown here had input to population 1, s1 = 0.8, and 
input to population 2, s2 = 17.  This resulted in a lower amplitude of the first peak 
and higher amplitude of the second peak. The reuptake of the second peak was 
faster in this simulation as a result of the extracellular serotonin remaining in the 
range necessary for Uptake 2 to function up to t = 30 sec.  
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Response (v).  This response was simulated in the model by setting the input of 
population 1, s1 = 0.8, and population 2, s2 = 2, and reducing the diffusion length 
between Dmn1 and Dmn2. The basal level of serotonin was in the lower range so 
serotonin was reuptaken by Uptake 1 transporters, because Uptake 2 transporters 
were inactive. 
Response (vi). In the experimental curve in Figure 2.2B.vi, which this simulation 
resembles, the first peak was lower in amplitude than the second, while the second 
peak occurred earlier in time than in the other curves shown. This effect was 
produced in the model simulation with input of the population 1, s1 = 0.6, and 
shortening the diffusion length from Dmn2 to Dmn1. The resulting curve showed a 
pulse of extracellular serotonin from Dmn2 arriving earlier to the electrode, in 
Dmn1.  
These simulations, generated with our new model, described the features of the 
experimental serotonin responses observed in the mPFC. Additional simulations (not 
shown) with varying parameters can give a multitude of other single and double-peak 
shapes of response curves. Thus, this mathematical model accurately supports the 
hypothesis that we constructed based upon our experimental data. 
2.4. CONCLUSION 
The medial prefrontal cortex plays a critical role in a variety of functions and 
behaviors. In working towards characterizing the functionality of the mPFC, we directed 
our efforts towards delineating serotonin transmission in this area. The application of 
FSCV and FSCAV allowed us the capacity to, for the first time, produce real-time in vivo 
serotonin measurements in the mPFC. We had previously modeled evoked serotonin 
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release in the substantia nigra, pars reticulata, and identified two clearance mechanisms: 
Uptake 1 and Uptake 2, each mediated by different transporters 21. Our current work in the 
mPFC, presented here, revealed two distinct evoked serotonin events, resulting from a 
single stimulation of the MFB, which were each bound to a discrete reuptake profile. We 
hypothesized that distinct populations of serotonin axons traverse the MFB and terminate 
in discrete reuptake domains. This hypothesis was explored and substantiated via 
pharmacology, histology, and mathematical modeling. In this work, we presented evidence 
for the complex organization and regulation of serotonin transmission in the mPFC. The 
model developed from this work lays the groundwork for our future studies of the function 
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3.1 INTRODUCTION 
Neuromodulators, such as serotonin, are thought to regulate the brain’s major 
excitatory and inhibitory processes. As such, subtle alterations in the function of these 
modulators are thought to underlie the phenotypes of many disorders of the brain 6, 56-59. 
To better understand the functional importance of messengers like serotonin in the brain, 
analytical measurements of neurotransmitters is a thriving and rapidly evolving field 60-62. 
To this end, we have thus far focused on pioneering in vivo measurements of evoked and 
ambient serotonin using fast-scan cyclic voltammetry (FSCV) and fast-scan controlled 
adsorption voltammetry (FSCAV) at carbon fiber microelectrodes (CFMs) 22, 23. 
Quantitative chemical measurements of brain serotonin in vivo are highly 
challenging because of very low extracellular concentrations 63. An additional difficulty 
for electroanalytical measurements is that serotonin and serotonin metabolites are 
detrimental to electrode stability due to polymer filming 20. In our initial efforts to develop 
an FSCV tool for serotonin measurements, we chose to make measurements in the 
substantia nigra, pars reticulata (SNr) because this region contains the most dense 
innervation by serotonin axons in the brain 64. When it comes to interest in serotonin’s 
actions in the brain however, there is much focus on psychiatric, cognitive and 
developmental disorders 6, 56-59 which implicate brain regions other than the SNr. These 
brain regions include the hippocampus 65, amygdala 66, hypothalamus 67 and prefrontal 
cortex (PFC) 68. Our own research interests incline us towards the hippocampus and medial 
prefrontal cortex (mPFC). Biophysical alterations are seen in these regions during disease. 
For example, volume changes in the hippocampus and the prefrontal cortex have been 
associated with depression 69-72 
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It is very important to address the chemical functionality associated with such 
biophysical changes. We have performed pilot studies in these and other brain areas 22, 73, 
74, here we present a formal characterization of the voltammetry stimulation and 
measurement circuits for serotonin in the CA2 region of the hippocampus and the mPFC, 
compared with the SNr. 
Serotonin is shown to be evoked in the CA2 region of the hippocampus, the mPFC 
and the SNr via a common electrical stimulation of the medial forebrain bundle (MFB). 
Comparison of the evoked and ambient serotonin chemistry in these three regions reveals 
significant differences which we postulate to arise from differences in tissue physiology 
local to the CFM, specifically in the characteristics of serotonin reuptake via different 
monoamine transporters. The chemical signals are modeled mathematically according to 
our previously established models of serotonin transmission which accounts for Uptake 1 
(Serotonin transporter (SERT) mediated) and Uptake 2 (Dopamine transporter (DAT), 
norepinephrine transporter (NET), and organic cation transporter (OCT) mediated) 21 and 
single vs. dual evoked events 73. Our modeling also, independently, hypothesizes 
differences in how serotonin is reuptaken via Uptake 1 and 2, while bringing forth 
additional hypotheses about the strength of input to the three locales and autoreceptor 
contribution. Our models’ predictions are subsequently verified with confocal imaging of 
axons and stimulation parameter experiments. 
We thereby show that FSCV and FSCAV are multi-faceted tools that provide 
information on the proteins directly around the CFM and tell us about the strength of the 
input circuit. This combination of techniques presents an innovative approach for chemical 
brain mapping which has future implications for chemically defining the functionality of 
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local circuitry during health and disease. A better understanding of the circuits within 
specific brain regions will ultimately allow for improved drug targeting for disease 
treatment. 
3.2 MATERIALS AND METHODS 
3.2.1 STUDY DESIGN AND EXCLUSION CRITERIA 
Previously collected sample data (see Appendix B) informed upon values necessary 
to determine statistical difference between two serotonin signals. This data was input into 
a power analysis according to literature standards 75. The following formula to calculate 
sample size between two groups with a quantitative endpoint was used: 
𝑛 = 2 × 𝑆𝐷2 × (𝑍𝛼 + 𝑍𝛽)/𝑑2 
The pooled standard deviation from the sample data was found to be 1.06, and the 
effect size 1.96, resulting in a calculated Cohen’s d of 1.85 76. The Zα term used was 1.96 
according to a 95% confidence interval and the Zβ term was 0.842 according to the 80% 
power assumed. This power analysis resulted in a n=5.25, which was rounded to 5. Finally, 
the sample size was corrected to account for loss of animals due to death or exclusion 
criteria75. We began with 141 animals to accommodate this adjustment and still achieve 
sufficient power. The percent of animals expected to die due to urethane anesthesia, based 
on empirical observations from our own lab, was about 38% (54of 141 animals). This 
number appears high, though research has shown that many studies severely under-report 
unexpected death from anesthesia77. Urethane is a terminal anesthetic and the dose is 
difficult to adjust. However, the fact that our experiments require long periods of stable 
anesthesia, combined with the non-survival nature of our experiments makes urethane an 
ideal choice for our purposes. Of the remaining 87 animals, 34 were excluded for because 
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of exclusion criteria fully detailed below, leaving 53 animals that were included in the data 
analysis (16 in the SNr, 16 in the CA2 and 21 in the mPFC). No randomization was used 
to determine which mice would be used for measurement in each region. 
For all FSCV experiments, the CV of the evoked signal was compared to well-
established serotonin cyclic voltammograms (CVs) in vivo and in vitro and mice in which 
the CVs did not contain the characteristic serotonin redox peaks or included interference 
by dopamine were excluded. For FSCAV experiments, a stimulated serotonin response was 
collected prior to the start of FSCAV and the same aforementioned test was performed. 
Data which contained a stimulation artifact resulting from the stimulation electrode 
touching the skull that masked, delayed, or minimized the serotonin response (stimulation 
glitch) were excluded. Electrodes that displayed drift or instability during file collection, 
as a result of damage during insertion, were excluded. While stereotaxic technique was 
utilized for this study, individual variation between mice often times limits the control we 
have over the exact position of the working electrode. We confirmed placement of the 
electrode in our target region in two ways, first during surgery, if the cyclic voltammogram 
is characteristic for serotonin and second, post-surgery histology confirmed if the electrode 
was in the target region. Signals not collected in the target regions were excluded from the 
study.  
3.2.2 CARBON-FIBER MICROELECTRODES 
CFM’s were constructed through the aspiration of a single T-650 carbon fiber (7 
μm, Goodfellow, Coraopolis, PA) through a cylindrical glass capillary (internal diameter: 
0.4 mm, external diameter: 0.6 mm, Product # 624500, A-M Systems, Carlsborg, WA). 
This capillary was then placed in a vertical pipette puller (Narishige Group, Setagaya-Ku, 
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Tokyo, Japan) to make a carbon – glass seal by gravity. The protruding carbon fiber was 
then cut to 150 μm in length. Subsequently, a solution of Nafion (LQ-1105-US-25, 5% by 
weight Nafion, Ion Power, DE) was electrodeposited, as previously described, onto the 
exposed carbon fiber 23. The CFM was then dried for 10 minutes at 70°C. 
 
 
Figure 3.1. Methods Diagram. In each of the three brain regions (CA2, SNr, mPFC) 
serotonin measurements were taken using either FSCV or FSCAV. The three main 
methods, outlined here, led to the collection of evoked control (SNr: n=5, CA2: n=5, 
mPFC: n=10), evoked stimulation parameter experiments (SNr: n=5, CA2: n=5, mPFC: 
n=5),  and basal (SNr: n=5, CA2: n=5, mPFC: n=5) serotonin measurements, and staining 
of serotonin axons (SNr: n=1, CA2: n=1, mPFC: n=1) in each of the three regions of 
interest. (n= number of animals) 
 
3.2.3 ANIMAL SURGERY 
C57BL/6J (RRID: IMSR_JAX:000664) male mice, 6 to 12 weeks old and between 
20-30 g, were procured from Jackson Laboratories (Bar Harbor, ME). The study was 
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originally started with 156 mice. Mice were offered food and water ad libitum and housed 
in 12 hours light/dark cycles. The Guide for the Care and Use of Laboratory Animals, as 
accepted by the Institutional Animal Care and Use Committees of the University of South 
Carolina (Institution Approval # A3049-01), was followed in all animal care and 
procedures. A urethane solution was produced (25% (w/v)) by dissolving urethane 
(Product # U2500, Sigma Aldrich Co., St. Louis, MO, USA) in sterile saline (0.9% NaCl 
solution, NDC 0409-4888-20, Hospira, Lake Forest, IL). The anesthetic urethane, was 
administered intraperitoneally (i.p.) at a volume of 7 μL per 1 g mouse weight, followed 
by stereotaxic surgeries (Model 962, David Kopf Instruments, Tujunga, CA) during the 
light cycle. To maintain the ideal mouse body temperature of 37° C, a heating pad from 
Braintree Scientific was utilized. For stereotaxic coordinates of MFB [AP: -1.58, ML: +1.0, 
DV: -4.8 to -5.0], SNr [AP: -3.28, ML: +1.40, DV: -4.21 to -5.0] CA2 [AP: -2.9, ML: 
+3.35, DV: -2.5 to -3.0], and mPFC [AP: +1.7, ML: +0.2, DV: -2.0 to -3.0], bregma was 
used as a reference from Franklin and Paxinos (2008). In order to access the MFB, CA2, 
SNr, and mPFC holes were drilled in line with the above stereotaxic coordinates. No 
randomization method was used to assign mice for measurements in a specific region. For 
stimulation, a stainless-steel electrode (diameter 0.2 mm, MS303/2-A/SPC; Plastics One, 
Roanoke, VA) was inserted into the MFB. For measurements, the Nafion-coated CFM was 
then inserted into either the CA2, SNr, or the mPFC. The reference electrode is made of a 
silver wire (diameter: 0.010 in, 787000; A-M Systems, Sequim, WA), which was 
electroplated with chloride through immersion of in hydrochloric acid for 30 seconds (0.1 
M, 4 V vs. tungsten). This is then placed into the contralateral hemisphere of the CFM 
placement. 
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3.2.4 DATA COLLECTION 
FSCV and FSCAV were both performed through instrumentation and software 
(WCCV 3.05) developed by Knowmad Technologies LLC (Tucson, AZ) (available upon 
request). FSCV was performed by applying the “Jackson” waveform 20. Measurements 
were collected every 10 minutes with a 30-60 second file. Five seconds into the file, a 
stimulation was applied (60 Hz biphasic 360 μA, 120 pulse stimulation, 2 ms per phase) 
through employing a linear constant current stimulus isolator (NL800A Neurolog; 
Digitimer Ltd.) to elicit the serotonin response. This stimulation was varied slightly, one 
parameter at a time, for the stimulation parameter experiments. FSCAV was applied 
through a CMOS precision analog switch, ADG419 (Analog Devices), which is used to 
control the application of the computer-generated “Jackson” waveform to the CFM. The 
logic was software - controlled to either apply a series of ramps (0.2 V to 1.0 V to -0.1 V 
to 0.2 V, scan rate = 1000 V/s) every 10 ms (100 Hz) or apply a constant potential of 0.2 
V to the CFM for a specified controlled adsorption period (10 s) 22. 
3.2.5 DATA ANALYSIS 
Signals collected from FSCV and FSCAV were processed using custom software 
(vide supra) using LabVIEW 2009 (available upon request). The processing used includes 
signal deconvolution, filtering, and smoothing. For FSCAV, the cyclic voltammogram 
(CV) at the 3rd scan (following the controlled adsorption period) was extracted to integrate 
the serotonin oxidation peak approximately between 0.4 V and 0.85 V. The charge value 
found, in pC, was plotted versus [serotonin] to generate calibration curves that were then 
used to calculate in vivo values which were specific to each electrode 22. No blinding was 
necessary for the purpose of the experiments presented herein. 
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3.2.6 STATISTICAL ANALYSIS 
Post-Hoc Validation of Sample Size: A sample size of 5 mice for each of the three 
groups was utilized. This choice of sample size was initially estimated by previous studies 
(see Study Design) as the data necessary for proper sample size calculation was not yet 
collected. Following collection of experimental data, this sample size was reevaluated 
based on power considerations. We assumed that two-sample t-tests applied at 5% level of 
significance and an 80% power with a Cohen’s d of 2.0 (associated with an effect size of 
2), when the common standard deviation is 1.0. Note that based on the obtained sample 
data, the pooled standard deviation was found to be 1.06, which is close to 1.0. Based on 
the sample size formula, the appropriate sample size to use is thus n = 3.92, rounded to a 
sample size of 4 for each group. Taking into consideration that the assumed common 
standard deviation of 1.0 may have been too liberal (in light of the sample standard 
deviation of 1.06), a sample size of 5 per group appears acceptable for determining 
statistical differences.  
Basal Level Analysis: In vitro calibrations related charge with the concentration, as 
explained previously 22.  We compared the basal responses for the three regions (CA2, SNr, 
mPFC; five animals for each region), where the basal value was measured every minute 
for 60 minutes. Hence, a repeated measures two-factor model was fitted, with the factors 
being the region and time. To accommodate the repeated-measures feature, random effects 
were included in the model, as well as the possible interaction effects between region and 
time. The model developed is presented here: 
Y(I,j,t) = M + A(i) + B(t) + C(i,t) + V(I,j) + E(I,j,t) 
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Where i = 1, 2, 3 represents the region; j = 1, 2, …, 5, represents the animal number 
(within the group), and t = 0, 1, 2, …, 60, represents the time. M is a common mean; the 
A(i)’s are the effects of the region levels; the B(t)’s are the effects of the time levels; the 
C(I,t)’s are the interaction effects; V(i,j) is a random term (which is normally distributed) 
to account for the repeated measurements over time; and E(I,j,t)’s are the error terms 
(which are also normally distributed and independent of the V(I,j)’s).  
A test of the null hypotheses that the B(t)’s and C(I,t)’s are all zeros based on the 
repeated-measures analysis of deviance, implemented through the R Statistical Package, 
resulted in not being able to reject these null hypotheses, hence both the interaction effect  
and the time effect were not significant.  The p-value for testing for no interaction effects 
was 0.8539, while the p-value for testing that there is no time effect is 0.8249. 
Because the time and region*time effects were not significant, we therefore 
combined the concentration over the 60 minutes for each of the animals in each group by 
obtaining their sample means. These sample mean values were then used to compare 
whether there were differences between the three regions; this analysis was performed 
using a one-way analysis of variance (ANOVA). By analyzing the sample means of the 
observations over time, we were able to eliminate dependencies over time among the 
observations. This analysis of variance showed that at least two of the regions are indeed 
different statistically with a p-value of 0.00000756 (ANOVA).  
To determine which regions are different, we performed pairwise t-tests with the 
Welch-Sattertwaite’s degrees-of-freedom approximation to allow for unequal variances, 
and we implemented a multiple testing correction, using the Holm procedure. We 
concluded that CA2 and mPFC regions are not statistically different (adjusted p = 0.23), 
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while the SNr and CA2 are different (adjusted p = 0.000012), and the SNr and mPFC are 
also different (adjusted p = 0.000043). A summary of the statistics from these group means 
are provided in Table 3.1 below, which includes 95% confidence interval for the group 
means.  











95% CI for the group 
mean response 
SNr 5 39.706 4.391 5.452 34.254 - 45.158 
CA2 5 72.822 7.170 8.903 63.919 - 81.725 
mPFC 5 67.565 7.636 9.481 58.084 - 77.046 
 
Depletion Analysis: Repeated stimulations were employed to determine if serotonin 
release could be depleted in each of the three regions over time. Maximum serotonin 
release for each animal in each group was measured in response to stimulations every 
minute for 20 minutes. The main goal was to compare the maximum amplitude during the 
first stimulation (t=1) with those at later times to see whether serotonin release was 
depleted in response to repeated stimulations. Because this is a repeated measures 
experiment, for any fixed time t (taking values from 2, 3, …, 20), we took the differences 
in the level at time t and at time 1 for each of the animals within each group. Using these 
differences, we then performed a one-sample t-test to test the null hypothesis that the 
population mean difference is zero versus less than zero (indicating a decrease from time 
1 to time t). We performed this procedure for each of the time values t, yielding a t-test 
statistic value and a p-value. Since we performed multiple tests (19), we applied the 
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Benjamini-Hochberg (BH) false discovery rate (FDR) mulitplicity correction. The results 
are as follows, based on the BH-adjusted p-values:  
For the CA2 data set, we concluded that the maximum amplitude at t=20 is 
significantly lower than at t=1, with BH-adjusted p-value of 0.0325. This is the only time 
point for which we concluded significance based on the BH-adjusted p-values. It should 
be noted that some of the unadjusted p-values arising from these t-tests were less than .05, 
however the necessity of the multiplicity adjustments increased these values. It is possible 
that with more animals, statistical significance could be achieved. Another way to globally 
test if the serotonin level was decreasing over time is via an analysis of covariance with the 
covariate being the serotonin level at t=1. This analysis of covariance yielded an estimate 
of the regression coefficient associated with time of -0.4542 (p-value = 0.00048) and with 
estimate of the coefficient of determination of R2 = 59.66%. The sign of the estimated 
regression coefficient (negative), indicates that the serotonin level decreases over time 
from t=1. 
For the SNr data set, we did not find any significant differences between t=1 and 
any of the other time points, even before the BH adjustment for multiplicity.  An analysis 
of covariance also did not show a significant decrease. 
For the mPFc data set, prior to the BH multiplicity adjustments, there were p-values 
that were less than 0.05. After employing the BH-adjustments the analysis concluded no 
significant differences between the t=1 and later time values. An analysis of covariance did 
not show a significant difference in the serotonin level over time. 
3.2.7 MODELING 











S(t) is the concentration of serotonin in the extracellular space, R(t) is the firing rate of the 
serotonin neuron that rises briefly after stimulation, and A(t) represents the strength of the 
autoreceptor effect. The first negative term represents reuptake by SERTs with Vmax1 = 
19.25 nM/hr and Km1 = 5 nM. The second term represents Uptake 2 (DATs, NETs, and 
OCTs) with Vmax2 = 780 nM/hr and Km2 = 170 nM. Uptake 2 operates only above the steady 
state concentration of serotonin. α and β give the balance between Uptake 1 and Uptake 2. 
For details and discussion, see Wood et al. 2014. To model the double hump in the mPFC 
we use the extended model presented in West et al. 2018 that allows diffusion of serotonin 
from regions with only Uptake 1 to regions that have both Uptake 1 and Uptake 2. 
3.2.8 HISTOLOGY 
In order to confirm the spatial placement of the CFM in vivo, a small lesion was 
created at the end of the FSCV experiment, by applying a constant potential at the CFM 
(~10 V for 1 min). Subsequently, the mice were euthanized via cervical dislocation 
followed by decapitation, and the brain was removed from the skull and stored in 4% 
paraformaldehyde in PBS solution. At least 2 days prior to sectioning, the brain was 
transferred into a 30% sucrose solution, until it was saturated with the medium. The brain 
was then flash-frozen, sectioned into 30 μm slices mounted onto frosted glass slides, and 
stained with 0.2% thionin. The slices were then photographed with an optical microscope. 
3.2.9 IMMUNOHISTOCHEMISTRY 
Slc6a4-EGFP male mice (RRID: MMRRC_030692-UCD), 6-12 weeks old, were 
anesthetized with urethane (25% dissolved in 0.9% NaCl solution, Hospira, Lake Forest, 
IL) administered intraperitoneally (i.p.) at a volume of 7 μL per 1 g mouse weight. Mice 
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were then perfused intracardially with phosphate-buffered saline (PBS) followed by 4% 
paraformaldehyde in PBS at 4 °C.  The entire brain was removed and fixed in 4% 
paraformaldehyde for 3 hours at room temperature and then cryoprotected in 15% sucrose 
in PBS overnight at 4 °C, followed by a switch to 30% sucrose on the next day and 
continuing overnight.  Sections of the mouse brain (40 µm thick) were prepared using a 
microtome and were washed with PBS and then blocked with 5% normal goat serum and 
0.3 % Triton X-100 in PBS for 2 hours at room temperature.  The sections were incubated 
in primary antibody diluted in blocking buffer, overnight at 4 °C. The primary antibodies 
used were chicken anti-GFP (1:5000, Aves Labs #GFP-1010, RRID: AB_2307313), 
guinea pig anti-SERT (1: 1,000, Frontier Institute #HTT-GP-Af1400), rabbit anti-TH (1: 
1,000, Millipore #AB152), and mouse anti-NeuN (1:500, Millipore #MAB377, RRID: 
AB_2298772). The sections were then washed with PBS and incubated in the secondary 
antibody in a blocking buffer for 2 hours at room temperature.  The secondary antibodies 
used were Alexa Fluor 488-labeled goat anti-chicken (1:1000, Life Technologies 
#A11039), Cy3-labeled goat anti-guinea pig (1:800, Jackson ImmunoResearch 
Laboratories #106-165-003), Cy3-labeled goat anti-rabbit (1:800, Jackson 
ImmunoResearch Laboratories #111-165-003), and Cy5-labeled goat anti-mouse (1:200, 
Jackson ImmunoResearch Laboratories #115-175-146). Then, the sections were mounted 
on slides, and images were acquired using a single-photon confocal microscope (Zeiss). 
Maximum projection images of 10 z-planes 1 micron apart were analyzed using NIH 
ImageJ (https://imagej.nih.gov/ij/), and % pixel intensity of EGFP signal above threshold 
was measured as an index of SERT innervation. 
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3.3 RESULTS  
3.3.1 SEROTONIN IS EVOKED VIA A COMMON MFB STIMULATION IN THREE 
DISTINCT BRAIN REGIONS 
 
 
Figure 3.2. Representative Serotonin Signals of the Three Regions. (i) Representation of a 
sagittal section of a mouse brain. WE shows the position of the working electrode and 
STIM shows the stimulating electrode. Green track represents the serotonergic axons that 
originate in the raphe nucleus and traverse the MFB to innervate different brain regions. 
(ii) Representative FSCV color plots of the CA2 (A) (n=5), the mPFC (B) (n=5) and (C) 
(n=5), and the SNr (D) (n=5). The red bar below the color plots denote the stimulation 
period (2 s) iii) Cyclic voltammograms extracted from the vertical dashed lines in A(ii), 
B(ii), C(ii), and D(ii) with current on the y-axis and voltage vs. Ag / AgCl on the x-axis.  
Red and yellow stars on C(ii) denote the two successive oxidation events seen in the mPFC.  
Cyclic voltammograms extracted at both these positions are seen in C(iii), marked with 
their respective stars. (n=number of animals) 
 
Stimulation of the MFB at one location evokes serotonin in the CA2 region of the 
hippocampus, the mPFC and the SNr.  Figure 3.2 displays representative examples of color 
plots and CVs collected in each of these 3 brain areas upon stimulation. In Panel i are 
illustrations of the positions of the stimulating and working electrode in sagittal sections of 
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the mouse brain. Panel ii shows representative 30 second color plots enveloping the 5 
seconds before and 25 seconds after the stimulation. Interpretation of color plots is 
explained in detail elsewhere 78, briefly voltage is on the y-axis, time on the x-axis, and 
current illustrated in false color. Panel iii shows CVs extracted from the vertical dashed 
lines on the color plots with the oxidation peak of serotonin at approximately 0.7 V.  
In contrast to the CA2 and SNr where a single serotonin release and uptake event 
is evoked upon stimulation, in the mPFC we often also observe a dual peak, the origins of 
which we’ve recently described 73. Two representative examples of mPFC signals are 
illustrated in Figure 3.2C.  
To study whether there is physiological relevant information in these traces, we 
carry out a comparison of how serotonin concentration changes over the file collection 
time. Serotonin concentration [serotonin] vs. time traces are extracted at the position of the 
peak oxidation current and averaged between 5 animals per region. Figure 3.3 shows the 
averaged serotonin time courses per region (n=5, ± standard error of the mean ((SEM)).  
The responses are confirmed to be in the target region via lesioning the tissue adjacent to 
the CFM after the experiment. A representative stained slice from each region, along with 
the location of the CFM, for each experiment performed can be found in Panel B of Figure 
3.3. The decay of these traces indicates the transporters responsible for removing serotonin 
from the extracellular space. A fast decay is a result of Uptake 2 (DATs, NETs, and OCTs), 
a slow decay results from Uptake 1 (SERTs), and a trace which has both fast and slow 
decay is a hybrid response and results from a combination of the two uptakes. Serotonin 
release in the CA2 appears primarily mediated by Uptake 2. The mPFC serotonin 
responses, as we previously characterized 73, involve clearance by both Uptake 1 and 2 
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transporters, which are linked inextricably to the two release domains. 
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Figure 3.3. Average Serotonin Concentration vs. Time Profiles and Histology.  
(A) Averaged [Serotonin] – time profiles (n=5 ± SEM) i) CA2, ii) mPFC 
single peak response, and iii) mPFC double peak response, and iv) SNr. 
Yellow bars beneath the plot denote the stimulation period (2 s). (B) Thionin 
stained representative brains displayed on the left with a colored circle 
denoting the actual placement of the CFM. On the right, yellow lines represent 
the outlines of the i) CA2 ii) mPFC, and iii) SNr regions. Blue, orange, and 
green circles denote the placement of the CFM in each individual mouse, for 
the CA2 (n=5), the SNr (n=5), and the mPFC (n=10), respectively. 
Coordinates with respect to Bregma are shown to the right of each coronal 
slice. Region specific coordinates are explained in the methods section. 
(n=number of animals) 
 
 Serotonin released in the first domain, observed as a single peak, is reuptaken by 
Uptake 2 mechanisms, while serotonin in the second domain is solely reuptaken by Uptake 
1 processes. This was verified pharmacologically using escitalopram. Domain 2 is only 
readily observed when measurements occur in layers 5-6 of the mPFC and is more sparsely 
innervated, resulting in a second peak due to the longer diffusion time to reach the electrode 
surface. In the SNr, serotonin seems to be reuptaken via a hybrid of Uptake 1 and 2.  
This data lead us to formulate a hypothesis that the chemical decay profile after 
stimulation offered by the CFM is indicative of the ratio of SERT (Uptake 1) : non-SERT 
(Uptake 2), specifically that serotonin in the SNr is cleared by a higher Uptake 1 : Uptake 
2 ratio when compared to the other two regions. To strengthen this hypothesis, we perform 
ambient serotonin measurements with FSCAV in the three brain areas, shown in Figure 
3.4. 
3.3.2 SEROTONIN BASAL LEVELS DIFFER BASED ON BRAIN REGION  
To measure ambient serotonin levels in each of three brain localities, a new method, 
FSCAV is applied 22. First MFB stimulation is employed in mice to verify the presence of 
serotonin with FSCV. FSCAV is then performed on the same CFM for 60 mins to obtain 
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a baseline reading of ambient serotonin concentrations. The dark blue, green, and orange 
circles on the central trace of Figure 3.4 represent the weighted average response (n=5 ± 
SEM) in the three regions. Individual mice traces are displayed by faint markers, of similar 
color, on the same plot. Representative in vivo color plots, along with CVs extracted from 
the 3rd scan (vertical dashed line), post controlled adsorption period, can be seen on Figure 
3.4. All CVs demonstrate the characteristic redox serotonin peaks, thus confirming the 
identity of the signal measured. To convert this signal to serotonin concentration in the 3 
zones, we use a chemometric approach, to take into account the variability between the 




Figure 3.4. Ambient Serotonin Concentrations. Blue, orange and green circles represent 
the weighted averaged response (n=5 mice each region ± SEM), and faint blue, orange, and 
green markers represent individual mice responses. Files were collected for 60 mins to 
obtain a baseline reading. Representative FSCAV color plots and CVs (extracted from 
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vertical dashed lines) are inset, on top left for the CA2, top right for the mPFC, and at the 
bottom for SNr. Yellow lines on the CV denote the limits of integration. ∗∗∗∗p<0.0001. 
 
Using 5 mice for each region, the average ambient serotonin level in the CA2 is 
72.82 ± 3.21 nM (n = 5 mice, weighted average ± standard error), the mPFC is 67.57 ± 
3.42 nM (n = 5 mice, weighted average ± standard error), whilst the level in the SNr is 
39.71 ± 1.96 nM (n = 5 mice, weighted average ± standard error). A pairwise t-test confirms 
statistically significant differences in the basal levels between the CA2 and SNr (p= 
0.000012), and the mPFC and SNr (p= 0.000043). While the CA2 and mPFC are not 
statistically different from one another (p= 0.23).  See the analysis reported earlier. 
3.3.3 MATHEMATICAL MODELING OF EVOKED RELEASE   
The ambient measurements support the idea that serotonin release in the SNr is 
reuptaken with a higher Uptake 1: Uptake 2 ratio than in the CA2 or mPFC. Here we 
analyze the experimental curves with previously established models and allow the model 
to generate an independent hypothesis to explain the experimental data. The model utilizes 
the Uptake 1, Uptake 2, autoreceptor, and two domain theories to determine the best 
parameters for fitting the experimental data presented here 21, 73.  Figure 3.5 shows the mean 
experimental curves for the CA2, mPFC and the SNr (solid are experimental and dotted 
are models). 
This analysis gives us an opportunity to compare the three areas by comparing the 
models’ parameters that were optimized to fit each curve. We allow ourselves to vary the 
strength of the input (R(t)), the strength of the autoreceptor effect (A(t)), and the strengths 
of Uptake 1 and Uptake 2 (α and β). And, to obtain the double hump in the mPFC, we 
allow diffusion from a region with only Uptake 1 to a region with both Uptake 1 and 2 (see 
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West et. al. 2018). The table in Figure 3.5 shows the qualitative differences in the 
parameters for different regions. 
 
 
Figure 3.5. Comparison of Experimental Data with Model Predictions. The [Serotonin] vs. 
time plots display the experimental data (solid) and model curves (dotted) for each region: 
CA2 (A), mPFC layers 5-6 (B), mPFC layers 1-3 (C), and the SNr (D). The table below 
outlines the parameters used to generate the model curves for each region. 
 
The results from the modeling are as follows: 
(a) Diffusion is needed to explain the double humps seen in the PFC. 
(b) There is higher contribution of Uptake 1 in the SNr than in the other regions. 
(c) The autoreceptor effect is strong in the SNr and CA2 but weak in the mPFC. 
(d) The input strength to regions of the mPFC is more variable than to the SNr and CA2. 
The model’s results bring forth 2 additional hypotheses, (b) and (d) that we are able 
to test below. 
3.3.4 IMAGING AXONAL DENSITY IN THREE BRAIN REGIONS 
To test the hypothesis brought forth by the model’s 2nd result (higher contribution 
of Uptake 1 in SNr) we employ a single photon imaging approach, whereby axons are 
imaged in brain slices of adult serotonin transporter-EGFP BAC transgenic mice 79. The 
imaging locations are chosen to correspond to the regions of our voltammetric 
measurements as ascertained with the histological analysis in Figure 3.3. Figure 3.6 shows 
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exemplar confocal images taken from the mPFC, CA2, and SNr from serotonin transporter-
EGFP BAC transgenic mice.  
To compare the degree of innervation between the regions, the percent pixels were 
calculated across the same number of focal planes for each region. The results, seen in 
Table 3.2, illustrate a higher degree of serotonin axon innervation in the SNr compared to 
the two regions (innervation depends on layer and sub-region of CA2 and mPFC). 
 
 
Figure 3.6. Immunohistochemical Staining. Immunohistochemistry for GFP in 
serotonin transporter-EGFP BAC transgenic mice reveals serotonin axon density 
across brain regions (n=1 mouse per region).  Top panels: The SERT signal is shown 
in green with NeuN in cyan in all regions except the prefrontal cortex layer 5 and 6 
where NeuN is shown in red. Layers 1-6 are all clearly defined in the prefrontal cortex 
and the stratum radiatum (Str. Rad.), stratum pyrimidale (Str. Pyr.), and the stratum 
oriens are labeled in the hippocampus.  In the SNr, the red immunofluorescence is 
signal from an antibody directed against tyrosine hydroxylase, a marker of dopamine 
neurons. The top panels show single photon confocal micrographs of axonal 
innervation in the three brain areas. The bottom panels show the green channel alone 






Table 3.2. Serotonin Axon Innervation 
 







SN Pars Reticulata 27.4 
mPFC 
L 1 19.7 
L 2/3 14.6 
L 5 17.4 
L 6 14.9 
 
3.3.5 AXONAL REACTION TO ELECTRICAL STIMULATION  
To test the hypothesis brought forth by the model’s 4th result (input strength to 
mPFC is more variable than other two regions) we perform a stimulation parameter study. 
Figure 3.7 (top panel) shows the maximum evoked concentration of serotonin after 
systematic variation of stimulation conditions frequency, amplitude and pulse width. This 
data shows that the axons react in a similar manner to stimulation since increased terminal 
serotonin accompanies increased stimulation intensity, frequency and pulse width. It is 
only the mPFC response that does not substantially plateau during any of the stimulation 
paradigms, whereas the CA2 and SNr responses plateau during one or more of the 
experiments (CA2 and SNr during amplitude and SNr during frequency). The plateau of 
the curves are confirmed utilizing the first derivative of each point with respect to the 
previous one. In one or more of the parameter studies, the first derivative of the CA2 and 
SNr data fall below zero, indicating that the slope is plateauing. A depletion study where 
serotonin release is stimulated once a minute over a one-hour period is shown in Figure 3.7 
(bottom panel). Here, when accounting for multiplicity, serotonin release in the CA2, but 
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in the SNr or mPFC, shows significant depleted over 20 stimulations (see Statistical 
Analysis section) 
 
Figure 3.7. Serotonin Axon Innervation. Top Panel– Averaged serotonin 
responses (n=5, ± SEM), CA2 (blue), mPFC (orange) and in the SNr (green) 
with variation in the stimulation frequency (top left), stimulation amplitude 
(middle), and stimulation pulse width (top right). Bottom Panel – Average 
serotonin response (n=5, ±SEM) to a stimulation train for 20 mins at 60 Hz, 4 
ms pulse width, and 360µA in the SNr (green), CA2 (blue), and mPFC 
(orange). (n=number of animals) 
 
3.4 DISCUSSION 
3.4.1 EXPANDING SEROTONIN VOLTAMMETRY BEYOND THE SNR 
In vivo FSCV measurements are largely limited to dopamine. Serotonin is 
significantly more problematic to electroanalyze in vivo for two reasons. First, during the 
oxidative scan, serotonin and similarly structured metabolites form unstable intermediary 
species that rapidly restabilize by forming polymers 20. Unfortunately, as this happens on 
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the electrode surface, serotonin films are created which poison the electrode. Second, 
extracellular serotonin levels are low, being subject to a thorough level of regulation, likely 
because of serotonin’s well-established neurotoxic effects 80. The former issue was largely 
resolved ex vivo via a combination of kinetic and physical modifications to the electrode 
and detection scheme 20, 23. The latter challenge was addressed by targeting an in vivo brain 
region with the highest density of serotonergic innervation, the SNr 64, under the rationale 
that the extracellular serotonin levels in that region should be high. Paradoxically, for 
reasons described below, we now know that extracellular serotonin levels in the SNr are 
not as high as in the other regions we studied. 
Recent interest in serotonin dynamics is largely for its roles in affective, cognitive 
and developmental disorders 6, 56-59. To investigate these diseases, brain regions other than 
the SNr are thought to play important roles. For example, the hippocampus is heavily 
implicated in emotion and memory, and as such is often the focus of depression studies 65. 
Similarly, the amygdala, nucleus accumbens, and hypothalamus are investigated for their 
roles in depression and anxiety 67, 81. The prefrontal cortex plays a role in controlling 
cognition, motor function, affective and social behaviors 25. The region also has a 
prolonged development period which means particular susceptibility to influence from 
exposure to environmental risk factors 82. As such, the PFC is often associated with and 
considered in the study of developmental disorders. General and our own interest in these 
regions shifted our efforts towards serotonin FSCV measurements in the CA2 region of the 
hippocampus and the mPFC.  
It is not trivial to simply apply our current FSCV approach to serotonin 
measurements in new brain regions. This is primarily because of interference from other 
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transmitters, metabolites and ions, and the heterogeneity of serotonin release sites within 
each region. Nonetheless, we optimized stereotaxic coordinates that yield serotonin FSCV 
signals in the CA2 region of the hippocampus, the mPFC and the SNr, in separate animals, 
through electrical stimulation of a common MFB site. Figure 3.2 shows 3 representative 
color plots and corresponding CVs for signals obtained in these regions. It is important to 
mention that the examples we choose in this figure are highly representative of the signals 
we obtain in each region. The color plots and CVs are different in these regions, with 
unique additional features, speak to the different interferences and microenvironment 
around the CFM. One such unique feature is the ‘switching’ peaks of each region that occur 
when analytes adsorb to the electrode surface and change the capacitative current that 
occurs as a function of the electrical bilayer on the electrode surface. This capacitative or 
charging current is normally subtracted out, however when analytes adsorb and change the 
current, a signal is manifested at the positive and negative switching potentials. It is not 
easily possible to identify which analytes are responsible for the switching peaks, but the 
switching peaks are different in region depending on the microenvironment. The 
characteristic serotonin oxidation peak is at around 0.7 V and we use this to quantify 
serotonin. Upon initial inspection of the CV, this peak can occasionally be difficult to 
observe due to the large switching peaks. However, upon closer inspection, including 
subtracting out the large switching peaks, the characteristic serotonin oxidation peak is 
observed.  
The mPFC is an intrinsically unique brain region in the context of evoked serotonin 
responses where two types of signals are routinely observed. In contrast to the CA2 and 
SNr where a single serotonin release and uptake event is evoked upon stimulation, in the 
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mPFC we often also observe a dual peak. We recently characterized mPFC responses and 
showed that the dual response was due to stimulation of two distinct axonal bundles that 
traverse the MFB with diffusion to the electrode surface resulting in the two distinct peaks. 
Each domain was also found to have a specific reuptake mechanisms (Uptake 1 or Uptake 
2) which was verified pharmacologically using escitalopram 73. 
These data thus confirm serotonin release in three regions via stimulation of the 
same MFB coordinate. This common stimulation site is significant because it will enable 
future, simultaneous measurements of serotonin in multiple brain localities in one animal.  
We perceive that the most striking feature of these responses is the difference in 
reuptake profiles. To better provide a visual comparison, in Figure 3.8, these responses are 
normalized such that the maximum amplitude in each case is at the level of the horizontal 
blue dotted line. In Wood et al. 2012, we modeled the uptake of serotonin in the SNr via 
two mechanisms, Uptake 1 and 2, first coined by Sol Snyder in the 1970s 37. Uptake 1 is 
reuptake by the serotonin transporters (SERTs) at high affinity and low efficiency. We 
observe the Uptake 1 mechanism as a single, slow decay curve (approx. 12-15 seconds). 
Uptake 2 transpires due to the activity of non-serotonin (non-SERT) transporters, that 
uptake serotonin with high efficiency, but with low capacity. Uptake 2 generates a decay 
curve with a single slope that reaches baseline quickly (around 5 seconds). When there is 
a combination of SERTs and non-SERTs, the result is a hybrid signal, with a curve that 
decays quickly for a few seconds, followed by a slow decay until it reaches baseline, 
resulting in decay with two different slopes 21.  
While the latter portions of the reuptake curves appear to be the most different 
between the curves, important information is garnered by comparing the entirety of the 
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reuptake profiles. Serotonin release in the CA2 appears primarily mediated by Uptake 2. 
The mPFC serotonin responses, as we previously characterized 73, involve clearance by 
both Uptake 1 and 2 transporters, which are linked inextricably to the two release domains. 
Serotonin released in the first domain, observed as a single peak, is reuptaken by Uptake 2 
mechanisms, while serotonin in the second domain is solely reuptaken by Uptake 1 
processes. Domain 2 is only readily observed when measurements occur in layers 5-6 of 
the mPFC. In the SNr, serotonin seems to be reuptaken via a hybrid of Uptake 1 and 
 
Figure 3.8. Comparison of Reuptake Curves. The averages from 
each region have been normalized such that the maximum 
amplitude of each curve is at the horizontal blue dotted line. This 
allows for simple visual comparison of the reuptake curves. 
 
This data lead us to formulate a hypothesis that the chemical decay profile after 
stimulation offered by the CFM is indicative of the ratio of SERT (Uptake 1) : non-SERT 
(Uptake 2) mediated serotonin reuptake. It follows that serotonin in the SNr and mPFC is 
more subject to Uptake 1 than serotonin in the CA2.  It is important to note that in the 
mPFC, we measure as many single evoked events mediated by Uptake 2 (exclusively in 
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layers 1-3) as we do double events (layers 5-6) incorporating both Uptake 1 and 2 73. For 
this reason, we narrow down our postulate to serotonin in the SNr being cleared by a higher 
Uptake 1 : Uptake 2 ratio when compared to the other two regions.  
To strengthen this hypothesis, we perform ambient serotonin measurements with 
FSCAV in the three brain areas, shown in Figure 3.4. In this study we find that extracellular 
serotonin levels in the SNr are significantly lower than in the other two regions. This 
finding is in contrast to our early rationale, that because the SNr is highly innervated by 
serotonin fibers and this region contains a high tissue content of serotonin, that the SNr 
should contain a higher extracellular serotonin concentration. 
We believe this low SNr basal level can also be explained by a higher ratio of SERT 
mediated reuptake in the SNr. At rest, ambient serotonin levels are primarily controlled by 
SERTs that are located, at high density, in the synaptic area 83. However, because serotonin 
communication is characterized by volume transmission, this modulator can escape the 
synapse where it is more likely cleared by Uptake 2 mechanisms. Our electrical MFB 
stimulation is intense, with a high frequency and as such causes an atypically heavy efflux 
of serotonin, large enough to significantly escape the synapse. Thus, we observe Uptake 2 
once the extracellular serotonin concentration is high enough to overcome a specific 
threshold. The stimulation allows us to test the local physiology of serotonin reuptake, yet 
the ambient level is more indicative of local SERT density (higher SERT density = lower 
extracellular serotonin). 
This finding further supports our hypothesis that the SNr serotonin is reuptaken by 
a higher Uptake 1 : Uptake 2 ratio. To corroborate the rationale, we next turned to 
computational models to analyze the experimental data. 
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3.4.2 MATHEMATICAL MODELING SUGGESTS PHYSIOLOGICAL 
DIFFERENCES AROUND CFM 
We bring forth the idea that serotonin release in the SNr is reuptaken with a higher 
Uptake 1: Uptake 2 ratio than in the CA2 or mPFC (vide supra). Here we use previously 
established models to model experiment data and generate independent hypotheses (Figure 
3.5). As a reminder, the conclusions from the modeling are:  
(a) Diffusion is needed to explain the double humps seen in the PFC. 
(b) There is a higher contribution of Uptake 1 in the SNr than in the other regions. 
(c) The autoreceptor effect is strong in the SNr and CA2 but weak in the mPFC. 
(d) The input strength to regions of the PFC is more variable than to the SNr and CA2. 
Result (a) has already been validated and discussed in detail in prior work 73. Conclusion 
(b) is in line with hypotheses brought forth from experimental data. The model has 
additionally suggested two more ideas in conclusions (c) and (d). We next further verify 
the Uptake 1 : Uptake ratio 2 hypothesis and address these two novel concepts. 
3.4.3 VERIFICATION OF MODEL HYPOTHESES 
The data and modeling thus far are highly interesting in that they imply that the 
voltammetric signal can provide information about local tissue physiology and the 
voltammetric circuitry. According to our model, the SNr evoked serotonin is subject to a 
higher ratio of Uptake 1 vs. Uptake 2. It is not possible to say for certain, because the model 
reports a ratio, but this finding implies a higher density of SERTs in the SNr compared to 
the other regions. To address SERT density in each region, we first turned to the literature 
but were unable to find a single study that utilized a common technique to compare SERTs 
in the specific areas of all three regions we are interested in. Thus we employ a single 
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photon imaging approach, whereby axons are imaged in brain slices of adult serotonin 
transporter-EGFP BAC transgenic mice 79. It is well established that axonal innervation 
corresponds to SERT density 68.   Images of axons and subsequent quantification of density 
(Figure 3.6 and Table 3.1) illustrate a higher degree of serotonin axon innervation in the 
SNr compared to the two regions (innervation depends on layer and sub-region of CA2 and 
mPFC). This is consistent with our model’s hypothesis of higher ratio of Uptake 1 to 2 
serotonin reuptake in the SNr. Thus these images provide support for the experimental and 
model Uptake 1 : Uptake 2 hypothesis.  
We next explore an additional postulation offered by the model, that the excitation 
input to the mPFC is more variable than to the other two regions. While serotonin is elicited 
in all three regions via the common MFB stimulation, this does not mean that the 
stimulation location is optimal for evoking maximal serotonin in all regions. If the 
stimulation location is optimal for eliciting maximal serotonin in all areas, systematically 
increasing the stimulation intensity, frequency and width should provide three serotonin 
profiles that plateau with the same characteristic. Thus, we perform experiments in 5 
separate mice in each region whereby electrical stimulation frequency, amplitude and pulse 
width are systematically altered. The standard stimulation utilized in our FSCV 
experiments is 120 pulses at 60Hz and 360 µA, so the parameters are varied around this 
range Figure 3.7 (top panel). The results from the stimulation paradigm study show that 
while the axons react in a similar manner to stimulation, the mPFC response does not 
plateau during any of the stimulation trains, whereas the CA2 and SNr responses clearly 
plateau during one or more of the experiments. This experiment shows that the stimulation 
location is less optimal for evoking maximal serotonin release in the mPFC, in accord with 
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the model’s postulate that the excitation input to the mPFC is more variable than to the 
other two regions. 
An interesting side note is that a key difference between regions is observed during 
a depletion study where serotonin release is stimulated once a minute over a one-hour 
period in Figure 3.7 (bottom panel). Here, only CA2 serotonin release are significantly 
depleted over 20 stimulations while the SNr shows no depletion. A simplistic explanation 
for this difference is the tissue content differences between these regions, of which SNr 
contains much higher serotonin levels than the other regions (21.0 ± 1.6 ng/mg in the SNr 
vs. 0.98 ± 0.13 ng/mg in the hippocampus and 0.81 ± 0.065 ng/mg in the frontal cortex) 37, 
84. While it is worth noting that none of these experiments demonstrate the profound 
depletion that occurs in similar depletion studies with dopamine, this was previously 
attributed to the high cytosolic serotonin compared to the low amount released during each 
stimulation 39. 
Thus, independently, two of the model’s hypotheses are verified, again providing 
context that the chemical signals at the CFMs provide important information about 
localities and circuits. Another aspect of the model is to hypothesize that serotonin in the 
CA2 is more strongly autoregulated in comparison to the other two locals. It would be 
extremely challenging to independently verify this notion due to the large scope of 
serotonin autoreceptors and autoreceptor sub-types, and these autoreceptors’ ability to 
synergize. However, the chemical signal and modeling that allude to autoreceptor control 
provide direction for future interest in autoreceptor mediated serotonin regulation. 
In sum, serotonin neurochemistry is important to study in the context of many brain 
disorders. FSCV and FSCAV are important tools to probe in vivo serotonin chemistry. In 
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this paper, we compared two new voltammetric serotonin stimulation - measurement 
circuitries, in the CA2 region of the hippocampus and the mPFC, to well established SNr 
measurements. A common MFB stimulation evoked serotonin in all three brain localities 
where evoked and ambient serotonin were measured at the same electrode. We found 
differences in the serotonin chemistry between these three regions that we postulated to 
arise from differences in tissue physiology local to the CFM. By taking mathematical and 
imaging approaches, we validated this hypothesis. We therefore highlight the strength of 
fast voltammetric tools for providing physiological information that has implications for 
circuit mapping. A map of the circuits within specific brain regions ultimately allows for 
improved drug targeting for disease treatment.
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CHAPTER 4: 
FAST VOLTAMMETRY OF SEROTONIN REVEALS SIMILARITIES 
ACROSS GENETIC MODELS OF AUTISM SPECTRUM DISORDER 
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4.1 INTRODUCTION 
Autism spectrum disorder (ASD) is a developmental disorder affecting 1 in 68 
children in the United States8. This behavioral disorder can present with a large variety of 
symptoms, though 3 core common behaviors define it: communication deficits, repetitive 
behaviors and social abnormalities. The severity in which these symptoms present also 
varies widely, resulting in the spectrum upon which children are diagnosed. Some of these 
symptoms can be managed with behavioral therapy and medication, while others are often 
quite debilitating, all leading to a high cost of care for patients and their families85. The 
growing prevalence and high cost of care has resulted in a vast amount of research into the 
cause and treatment of the disorder, identifying genetic and environmental risk factors as 
having a significant role9, 86.  
Genetic studies, particularly sibling and twin studies87, have revealed that ASD may 
rest on a genetic foundation since over 1000 genes have been linked to the disorder10. To 
better understand the pathophysiology of ASD, we must focus on the known causes which 
can be used to generate animal models of the disorder. ASD animal models are traditionally 
assessed on behavioral phenotypes which are characteristic of the disorder in humans. 
Difficulty in replicating human behaviors in mice can result in inconsistencies in 
behavioral scoring and interpretation between labs, potentially discounting the validity of 
some genetic models.  This issues with model assessment would be alleviated if a common 
biomarker could be identified.  
In humans, high blood serotonin is arguably the most reproduceable biomarker, 
with 1 in 3 patients presenting with this phenotype14. Despite not all patients having 
hyperserotonemia, this high prevalence still warrants further examination; specifically, 
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investigation of serotonin in the brain. Serotonin plays many important roles as a 
neurotransmitter and is thought to be implicated in the behavioral phenotypes of ASD6, 88. 
Since serotonin cannot cross the blood brain barrier, the levels between the peripheral and 
central nervous system are not easily correlated and studying brain serotonin is further 
complicated by the fragile nature of the brain.  
Serotonin has been studied in the brain using a variety of techniques; however, to 
understand the functionality of the circuit and the processes that play a role in serotonin 
regulation, we need to utilize a technique capable of detecting serotonin in in-tact tissue in 
real-time. Fast-scan cyclic voltammetry (FSCV) is an ideal technique for this task as it is 
capable of recording the stimulated release and reuptake of serotonin in vivo. Recently, 
FSCV was used to characterize serotonin chemistry in the prefrontal cortex73, a region 
commonly associated with morphological changes in ASD patients and therefore an ideal 
place to begin investigations24. 
We begin our studies by looking at a model with a confirmed serotonin alteration, 
the SERT-Ala56 mouse. This model has been designed to present the high blood serotonin 
seen in 1/3rd of ASD patients89. It provides the unique opportunity to correlate serotonin 
brain chemistry with that of the peripheral nervous system. The genetic variation resulting 
in the SERT-Ala56 model has been observed in ASD patients and when this genetic 
alteration is present in mice14, it results in all three of the characteristic autism like 
behaviors89. 
A secondary model with no direct link to serotonin is used to determine if altered 
serotonin neurochemistry persists across multiple, diverse ASD models. This second model 
contains an alteration to the Shank3 gene and displays two of the three ASD typical 
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behaviors90. The Shank3 gene is scored with a high association through Simons Foundation 
Autism Research Initiative (SFARI), meaning the evidence linking this gene to ASD is 
strong. It is also a syndromic model offering the opportunity to study a genetic model linked 
to a disorder which can occur comorbidly with ASD. The Shank3 gene encodes the protein 
which creates the scaffolding between glutamatergic neurons91, 92. While this does not 
directly affect serotonin neurons, the excitatory nature of glutamate could lead to 
downstream effects on other neurotransmitters. 
Evaluating the serotonin chemistry in the brains of two distinct genetic models of 
ASD will allow us to determine if there are any underlying commonalities in the 
pathophysiology. 
4.2 METHODS 
4.2.1 BREEDING AND GENOTYPING 
The Guide for the Care and Use of Laboratory Animals, as accepted by the 
Institutional Animal Care and Use Committees of the University of South Carolina 
(Institution Approval # A3049-01), was followed in all animal care and procedures. 
C57BL/6J (RRID: IMSR_JAX:000664) mice, and B6(Cg)-Shank3tm1.2Bux/J (RRID: 
IMSR_JAX:017890) were procured from Jackson Laboratories (Bar Harbor, ME). SERT-
Ala56 mice were transferred from Dr. Randy Blakely at Florida Atlantic University. Mice 
were offered food and water ad libitum and housed in 12 hours light/dark cycles. Male and 
female mice were paired for breeding at 8 weeks old. Heterozygous- heterozygous pairings 
were used for SERT- Ala56 breeding and heterozygous-wildtype pairings were used for 
Shank3 breeding. Pups were weened at 21 days and a tail-snip obtained. The SERT-Ala56 
mice were genotyped utilizing Transnetyx services. The Shank3 mice were genotyped 
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using PCR with REDTaq ReadyMix (Sigma Aldrich), and following previously 
established genotyping protocol by the Jackson Laboratory. 
When the mice reached 7-12 weeks old, they underwent stereotaxic surgery and 
FSCV was used to evaluate their serotonin neurochemistry. 
4.2.2 CARBON-FIBER MICROELECTRODES 
Carbon fiber microelectrodes (CFMs) were generated in-house by aspiration of a 
single T-650 carbon fiber (7 μm, Goodfellow, Coraopolis, PA) through a cylindrical glass 
capillary (internal diameter: 0.4 mm, external diameter: 0.6 mm, Product # 624500, A-M 
Systems, Carlsborg, WA). A carbon – glass seal was made using a vertical pipette puller 
(Narishige Group, Setagaya-Ku, Tokyo, Japan). The protruding carbon fiber was cut to 150 
μm in length. A cation exchange polymer, Nafion (LQ-1105-US-25, 5% by weight Nafion, 
Ion Power, DE), was then electrodeposited onto the carbon fiber as previously described23.  
4.2.3 SURGERY AND FSCV 
A urethane solution (25% (w/v)) was made by dissolving urethane (Product # 
U2500, Sigma Aldrich Co., St. Louis, MO, USA) in sterile saline (0.9% NaCl solution, 
NDC 0409-4888-20, Hospira, Lake Forest, IL). When the mice were 7 to 12 weeks old 
they received an intraperitoneally (i.p.) injection of urethane solution at a volume of 7 μL 
per 1 g mouse weight. Once fully under the effects of the anesthesia, they underwent 
stereotaxic surgeries (Model 962, David Kopf Instruments, Tujunga, CA) during the light 
cycle. A heating pad from Braintree Scientific was used for maintaining the ideal mouse 
body temperature of 37° C. The stereotaxic coordinates for the MFB [AP: -1.58, ML: +1.0, 
DV: -4.8 to -5.0] and mPFC [AP: +1.7, ML: +0.2, DV: -2.0 to -3.0] were marked according 
to Franklin and Paxinos (2008), using bregma was used as a reference. Holes were drilled 
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at the marked stereotaxic coordinates, with an additional hole drilled in the contralateral 
hemisphere for the reference electrode. A pseudo Ag/AgCl reference electrode was used, 
made of a silver wire (diameter: 0.010 in, 787000; A-M Systems, Sequim, WA) 
electroplated with chloride through immersion in hydrochloric acid for 30 seconds (0.1 M, 
4 V vs. tungsten). A stainless-steel stimulation electrode (diameter 0.2 mm, MS303/2-
A/SPC; Plastics One, Roanoke, VA) was lowered into the MFB, and the Nafion-coated 
CFM was lowered into the mPFC.  
FSCV was performed through instrumentation and software (WCCV 3.06) 
developed by Knowmad Technologies LLC (Tucson, AZ). A serotonin selective 
waveform, known as the “Jackson” waveform 20, was applied to the CFM. A 30 second file 
was collected every 10 minutes; five seconds into the file, a stimulation was applied (60 
Hz biphasic 360 μA, 120 pulse stimulation, 2 ms per phase) using a linear constant current 
stimulus isolator (NL800A Neurolog; Digitimer Ltd.). Signals were processed using signal 
deconvolution, filtering, and smoothing in custom software using LabVIEW 2009.  
4.2.4 DATA ANALYSIS 
Signals were analyzed to compare the maximum amplitude and t1/2. The maximum 
amplitude was taken as the highest concentration of serotonin elicited following the 
stimulation. These values were compared using a one-way t-test. The t1/2 was calculated 
using the curve fitting tool with a custom equation for plotting exponential decay in 
MatLab R2018B, the natural log of 2 was divided by the mean lifetime yielded to calculate 
t1/2. One-way t-test were used to test for statistical significance. Statistical significance was 
defined as a p<0.05.  
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4.2.5 EXCLUSION CRITERIA 
For all FSCV experiments, the CV of the evoked signal was compared to well-
established serotonin cyclic voltammograms (CVs) in vivo and in vitro and signals which 
lacked the characteristic serotonin redox peaks were excluded. Signals which contained a 
peak resulting from the stimulation electrode touching the skull that masked, delayed, or 
minimized the serotonin response (stimulation glitch) were excluded. Electrodes that 
displayed instability during file collection were also excluded.  
4.2.6 HISTOLOGY 
To confirm the placement of the CFM in the targeted region in vivo, a small lesion 
was created at the end of the FSCV experiment by applying a constant potential at the CFM 
(~10 V for 1 min). The mice were then euthanized via cervical dislocation followed by 
decapitation, and the brain was removed from the skull and stored in 4% paraformaldehyde 
in PBS solution. The brain was transferred into a 30% sucrose solution prior to sectioning. 
Once the brain was saturated with the medium, it was then flash-frozen, sectioned into 30 
μm slices, mounted onto frosted glass slides, and the slices were then photographed with 
an optical microscope. Lesions were confirmed to be in the targeted regions. 
4.3 RESULTS AND DISCUSSION 
 The SERT-Ala56 mice appear to display differences in serotonin transmission in 
comparison to control animals. In SERT-Ala56 mice, evoked serotonin release has a lower 
maximum amplitude and is taken up at a faster rate than in control animals. This effect can 
be observed in Figure 4.1 where the average evoked serotonin release of the SERT-Ala56 
mice has been plotted along with an average control response. The peak concentration of 
serotonin released following stimulation (MaxA) and the time it takes to decay to half of 
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this amplitude (t½) was calculated for each animal’s serotonin response, as described above. 
These results are tallied in Table 4.1 along with the p-value outcomes of the t-test 
preformed to compare each measure.  
 
Figure 4.1. Evoked Release of SERT-Ala56 vs Control Mice. 
The evoked serotonin release (stimulation is noted by the 
yellow box) from SERT-Ala56 mice and Control mice have 
each been averaged and are compared here.  
 
Table 4.1. T1/2 and Maximum Release of SERT-Ala56 vs Mice. 
 
Identification T1/2 (s) MaxA (nM) 
Knock-In 1 1.206 17.45 
Knock-In 2 1.895 9.37 
Knock-In 3 0.866 9.86 
Knock-In 4 1.036 14.36 
Control 1 1.560 17.49 
Control 2 1.853 17.16 
Control 3 2.067 26.52 
Control 4 2.178 25.99 
T-Test p=0.0870 p=0.0155 
 
The faster reuptake and decreased amplitude found in these animals are both 
supported by previous data presented by Blakely and colleagues89. The significantly 
decreased amplitude observed in the SERT-Ala56 mice can be explained via two possible 
hypotheses. Blakely and colleagues demonstrated that these mice have overactive SERTs 
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which caused the animals to exhibit a faster rate of serotonin clearance89. These overactive 
transporters may potentially explain the decreased amplitude observed since the SERTs 
will restrict the amount of serotonin detected following stimulated release. This 
phenomenon has been observed previously in tissue slice preparations and Wightman et al. 
postulated it was a result of the uptake of serotonin occurring between the time of the 
stimulation pulses, restricting the summation of extracellular serotonin93. The second 
explanation for the decreased amplitude is hypersensitive autoreceptors. Autoreceptors are 
inhibitory receptors that when bound to serotonin provide negative feedback to inhibit the 
release of serotonin. Veenstra-VanderWeele et al. demonstrated that the SERT-Ala56 
genetic model displays increased autoreceptor activity, specifically naming the 5-HT1A and 
5-HT2A receptors
14, 89. The two explanations posited here may be at work, a theory further 
supported by the fact that 5-HT1B autoreceptors have been shown to modulate SERT
94.  
 The change in t1/2 observed was not statistically significant though an increased rate 
of serotonin clearance was also previously shown by Veenstra VanderWeele et al. using 
chronoamperometry89. Interestingly, previous models of FSCV serotonin dynamics 
indicate that the reuptake of a single peak in the prefrontal cortex is primarily mediated by 
other monoamine transporters such as dopamine transporters (DATs), norepinephrine 
transporters (NETs), and the organic cation transporters (OCTs)73. These transporters do 
not have a high affinity for serotonin but very efficiently reuptake serotonin.  However, if 
the SERTs are significantly overactive they may still contribute to the increased clearance 
observed here. 
The serotonin neurotransmission of Shank3 mice was compared to control animals 
and demonstrated unique features. Figure 4.2 displays the plot of the average evoked 
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serotonin release of the Shank3 mice over time along with an average control response. To 
evaluate the differences between the two cohorts, the peak concentration of serotonin 
released following stimulation (MaxA) and the time it takes to decay to half of this 
amplitude (t½) was calculated for each animal’s serotonin response, as described above. 
These results are tallied in Table 4.2 along with the p-values associated with the t-test 
preformed to compare each measure. Though no differences are found in the maximum 
evoked concentration of serotonin, the Shank3 mice do display a significantly faster 
reuptake.  
 
Figure 4.2. Evoked Release of Shank3 vs Control Mice. The 
evoked serotonin release (stimulation is noted by the yellow 
box) from Shank3 mice and Control mice have each been 
averaged and are compared here.  
 
Table 4.2. T1/2 and Maximum Release of Shank3 vs Control Mice. 
 
Identification T1/2 (s) MaxA (nM) 
Heterozygous 1 1.373 29.55 
Heterozygous 2 1.892 21.14 
Heterozygous 3 0.8328 17.44 
Heterozygous 4 1.406 31.50 
Control 1 1.560 17.49 
Control 2 1.853 17.16 
Control 3 2.067 26.52 
Control 4 2.178 25.99 
T-Test p=0.0399 p=0.245 
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 The statistically faster reuptake displayed by the Shank3 mice indicates that the one 
or more of the DATs, NETs, OCTs, and SERTs are more active than in the control animals. 
There is no direct association between the genetic modification of Shank3 and these 
transporters and thus indirect explanations must be considered. There is limited 
information on the neurochemical changes present in this genetic modification to 
rationalize changes to other neurotransmitter transporters. The original study of this model 
found that these mice display lower amplitude but higher frequency post-synaptic 
excitatory currents and have fewer AMPA receptors. Though the amplitude is lower, the 
higher frequency excitatory currents may result in more frequent glutamate firing90. As the 
primary excitatory neurotransmitter, glutamate would potentiate the release of other 
neurotransmitters including serotonin, norepinephrine, and dopamine. In turn, the higher 
frequency release could cause upregulation in DATs, NETs, OCTs, and SERTs to maintain 
the homeostasis of these neurotransmitters. While quantification of AMPA receptors has 
been previously determined, it was not determined that NMDA and mGluR receptors are 
not upregulated as a compensatory mechanism. If more of these receptors were present, 
they could also lead to an increase in release of dopamine, norepinephrine, and serotonin. 
While these theories cannot yet be confirmed, it is reasonable to state that the excitatory 
and inhibitory balance of neurotransmission is disrupted in the Shank3 mice due to 
alterations in glutamate transmission. This disruption has indirectly resulted in an increased 
reuptake rate of serotonin. 
A faster rate of serotonin reuptake is observed in both of these ASD models 
(Shank3 mice and SERT-Ala56) compared to control mice. This reuptake is primarily 
indicative of the non-SERTs including DATs, NETs, and OCTs73. In both genetic models, 
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it seems that these transporters more efficiently reuptake serotonin. Theories for this 
increased efficiency have been offered for both models, though they cannot be confirmed 
at this time. However, the faster reuptake of serotonin observed in the models provides an 
explanation for why selective serotonin reuptake inhibitors (SSRIs) are often prescribed as 
treatments for ASD and can be successful95. SSRIs work by blocking the reuptake of 
serotonin, and while these drugs are designed to have the highest affinity for SERT, many 
also display affinities for other monoamine transporters.  
To investigate the functionality of SERTs in these models, we must next analyze 
the  bi-phasic peaks often found in the prefrontal cortex and detailed in previous work73. 
This analysis will be the focus of future work and requires mathematical modeling for 




BEHAVIORAL AND VOLTAMMETRIC ANALYSIS OF PERINATAL 




 Knowledge of the detrimental health effects of lead (Pb2+) can be traced back to the 
2nd century B.C. and as our scientific tools have improved, the list of symptoms resulting 
from lead poisoning has grown96. While Pb2+ is harmful to the peripheral nervous system, 
the central nervous system is especially sensitive to Pb2+ since this small cation readily 
crosses the blood brain barrier (BBB) and is similar in structure and size to other small 
metal ions that are essential to brain function96, 97. The damage caused by Pb2+ in the brain 
is extensive and includes oxidative stress, mitochondrial dysfunction, neuroinflammation, 
protein turnover dysregulation, decreased cellular energy metabolism, lipid peroxidation, 
abnormal neurotrophic factor expression, and altered gene transcription97-99. Many of these 
issues are a direct result of Pb2+’s ability to mimic and compete with calcium (II) (Ca2+)100. 
This phenomenon also means that Pb2+ directly affects neuronal signaling with some 
studies reporting enhanced transient neurotransmission and inhibited stimulated release101.  
Over the last century it has been acknowledged that children are far more 
susceptible to lead poisoning than adults and that these effects persist across the lifespan. 
A number of factors contribute to this susceptibility including that children’s digestive 
systems more readily absorb Pb2+ and the developing brain is far more vulnerable102. 
Likewise, there is extreme concern of the exposure of pregnant and lactating women to 
Pb2+ as it can cross to the fetus and child through the placenta and milk ducts103, 104. In 
children exposed to Pb2+ during development, a myriad of symptoms have been reported 
to last long after exposure including cognitive, attention, and behavioral impairments105. 
These have been replicated in animal studies of lead exposure in utero which found that 
mice exposed to millimolar concentrations of Pb2+ from pregnancy up to weaning resulted 
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in learning and memory impairments106. Thus, early life and gestational Pb2+ exposure is 
highly implicated as a risk factor for developmental disorders. 
The large body of literature characterizing the many harmful effects of Pb2+ 
exposure, as well as the progressive reduction in the exposure levels being tested has 
caused the World Health Organization (WHO) to acknowledge that there is no safe level 
of lead exposure. Humans are exposed to Pb2+ from a variety of sources, including paint, 
leaded gasoline, cosmetics, fruit juices, and drinking water. The inclusion of Pb2+ in paint 
and gasoline has been banned in most countries, reducing the likelihood of exposure via 
those sources. As for cosmetics, fruit juices, and drinking water, regulatory agencies in the 
US have placed limits of 10 ppm, 50 ppb, and 15 ppb, respectively. Unfortunately, these 
standards are not always upheld, exposing populations to dangerous levels of Pb2+, often 
times without their knowledge. These were exactly the circumstances in the highly 
publicized cases of D.C and Flint, Michigan when local populations were exposed to 
extremely high levels of Pb2+ for months and in some cases years before the problem was 
addressed107, 108. While these events highlight the dangers of chronic exposure to high 
levels of Pb2+, they also beg the question, is the standard itself safe. The EPA acknowledges 
that the maximum contaminant level goal (MCLG) for Pb2+ is zero, yet based mostly on 
cost, the maximum contaminant level (MCL) is actually 15 ppb109.   
Pb2+ has been shown to induce inflammation in the peripheral and central nervous 
system. Acute exposure studies have found that Pb2+ accumulates in microglial cells and 
can cause astrocyte activation, while this ion can promote chronic glial cell activation with 
coexisting inflammatory and neurodegenerative features. Perinatal Pb2+ exposure studies in 
mice have revealed DNA methylation and gene expression alterations. Some of these genes 
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include those that play a role in immune system function and brain development. This could 
explain why studies have previously found impaired synapse formation and altered 
synaptic plasticity. In conjunction with these gene effects, vesicular release was also 
inhibited. It is thought that Pb2+ exposure disrupts excitatory and inhibitory (E/I) balance 
of neurotransmission due to action on GABA and glutamate, the primary inhibitory and 
excitatory neuromodulators, respectively.  
It remains to be seen what the exact effects of these many changes have on a 
molecule such as serotonin. As a neurotransmitter, serotonin will likely be disrupted by the 
inhibition of vesicular release. However, serotonin will also be affected by the changes in 
brain development as it also plays a role in this process16. Serotonin is also susceptible to 
regulation via inflammatory response110. Finally, serotonin is involved in learning and 
memory, which have been documented to be disrupted following Pb2+ exposure25, 96. The 
behavioral disruptions observed with Pb2+ exposure during development have given rise to 
the theory that Pb2+ may be a risk factor for autism spectrum disorder12, 111. Research so far 
has focused on Pb2+ exposure concentrations much higher than we explore in this paper98, 
99, 112. While the underlying pathophysiology of ASD is not fully understood, research 
strongly implicates alterations in brain serotonin, therefore we are interested in assessing 
the effects of Pb2+ on the serotonin system. 
In this paper, we determine the effects of acute and chronic Pb2+ exposure, at the 
EPA (Environmental Protection Agency) drinking water limit, on in vivo serotonin 
transmission. Specifically, we ask whether low level Pb2+ exposure during pregnancy and 




5.2 MATERIALS AND METHODS 
5.2.1 STUDY DESIGN 
The Guide for the Care and Use of Laboratory Animals, as accepted by the 
Institutional Animal Care and Use Committees of the University of South Carolina 
(Institution Approval # A3049-01), was followed in all animal care and procedures. 
C57BL/6J (RRID: IMSR_JAX:000664) mice, 6 weeks old were procured from Jackson 
Laboratories (Bar Harbor, ME). Mice were offered food and water ad libitum and housed 
in 12 hours light/dark cycles. Three separate paradigms were followed for acute, chronic, 
and perinatal exposures, the methods of which are as follows. For the acute exposure, mice 
between the ages of 7-9 weeks old underwent stereotaxic surgery and FSCV was used to 
evaluate their serotonin neurochemistry, control files were collected, and they were 
administered a bolus dose of 15 ppb lead acetate solution in saline (5 ml/kg). For the 
chronic exposure, 6-8 week old mice were exposed to either drinking water from animal 
facilities, which goes through a reverse osmosis filter, or the same water with 15 ppb lead 
acetate added to it, for one week. When the mice reached 7-9 weeks old, they then 
underwent stereotaxic surgery and FSCV was used to evaluate their serotonin 
neurochemistry. For the perinatal exposure, male and female mice were paired for breeding 
at 8 weeks old and upon being paired, mice were exposed to either drinking water from 
animal facilities, which goes through a reverse osmosis filter, or the same water with 15 
ppb lead acetate added to it. The male breeder was removed once the pups were born. The 
female breeder and pups were exposed to their respective drinking waters up until weening 
at which point the pups were all offered animal facility drinking water, without any lead 
added, ad libitum. When the perinatally exposed mice reached 8 weeks old, they underwent 
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a battery of behavior tests (described below). Following these tests, a short period was 
allowed for any stress the behavior tests may have caused to abate. Mice then underwent 
stereotaxic surgery and FSCV was used to evaluate their serotonin neurochemistry. 
5.2.2 BEHAVIORAL ANALYSIS 
When the mice were 8 weeks old, they underwent a series of behavior tests to assess 
autism-like behaviors. The tests were administered in the order they are described below 
with one day between the olfactory test and three-chamber test to reduce any effects of 
stress on test outcome. As the test order was selected to minimize stress, likewise the order 
in which animals were underwent each test was also determined in a manner to minimize 
stress effects on test outcome. For example, a mouse which was used as a “familiar mouse” 
in the three-chamber social approach would not subsequently be used as the test mouse on 
the same day. Prior to each test, mice were habituated to the behavior suite for at least one 
hour. Noldus Ethovision was employed for the recording and scoring of behavior tests 
when applicable.  
5.2.2.1 REPETITIVE BEHAVIOR 
Mice were singly housed for the duration of the behavior test and allowed a fifteen-
minute habituation period in the clean cage prior to the start of the test. Mice did not have 
access to food or water throughout the habituation and test periods. The duration of the test 
was fifteen minutes. The following behaviors were observed and scored: grooming, 
digging, rearing, and climbing. The test was hand scored by two researchers who were 
blinded to the identity of the mice. The number of times each behavior was observed was 
averaged for all mice in a cohort and the two cohorts (exposed vs control) were compared 
for each behavior. A t-test was used to test for any statistical differences.   
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5.2.2.2 MARBLE BURYING 
For the purpose of this test biofresh comfort bedding was used, as the natural 
cellulose fibers promote burrowing. Mice were habituated in singly housed cages with the 
biofresh comfort bedding for a period of ten minutes. Following habituation, mice were 
temporarily removed from the cage to place 12 marbles in a grid pattern on the bedding. 
Mice were returned to the cages and allowed a ten-minute test period, after which the 
marbles were scored as either buried, unburied, or partially buried. A partial burial 
constituted a marble which was still easily visible but also had some bedding on top of it. 
Again, two research blindly hand scored the outcome of the test. The results were compared 
as buried and unburied (assuming partial burial constituted buried) for exposed mice to 
control mice and a t-test was used to evaluate statistical significance.  
5.2.2.3 OLFACTORY HABITUATION/ DISHABITUATION 
In the olfactory habituation/dishabituation test, mice were singly house without 
access to food or water for the test and habituation period, with each period lasting 45 
minutes. A series of scents were introduced to the mice via a q-tip and the amount of time 
the mice spent sniffing each scent was recorded. Each scent was presented to the mice three 
times, each on a new q-tip, for a period of two minutes, with one minute between each 
presentation. The following scents were introduced in the order listed: water, orange 
extract, vanilla extract, social scent 1, social scent 2. Each social scent was taken as a swab 
from the bottom of a cage of unfamiliar mice containing 4-5 mice of the same sex as the 
test subject. The cage had not been changed for at least two days. The non-social smells 
were prepared as previously described 113. The two scoring researchers were again blind to 
the animal identity and the two tabulated scores averaged. The results were evaluated with 
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a multi-way analysis of variance (ANOVA), to test for habituation as well as difference in 
time spent sniffing social vs non-social smells in Pb2+ exposed vs control mice.  
5.2.2.4 THREE-CHAMBER SOCIAL APPROACH 
A custom built three chamber apparatus was utilized with dimensions according to 
commercially available equivalents from Ugo Basile. The cage cups used were purchased 
from Ugo Basile.  Mice were allowed a 5-minute habituation period in the center chamber 
without access to the other chambers, followed by a five-minute exploration period with 
access to all chambers and no other mice present in the apparatus. Following these periods, 
when the mouse returned to the center chamber, the doors were again closed and a familiar 
mouse (cage mate) was placed in one of the cups in one of the side chambers. The other 
side chamber contained an empty cup and the side used was chosen at random, though kept 
consistent for each test. For a ten-minute test period, the mouse was allowed access to all 
three chambers. Once the test period was complete and the mouse returned to the center 
chamber, the familiar mouse was removed, the cage cleaned, and a novel mouse of the 
same sex placed in that cup. The ten-minute test period was repeated. Noldus ethovision 
was used to score this test, scoring the time spent in each chamber by the mouse. Multi-
way ANOVAs were used to compare time spent in each chamber.  
5.2.2.5 ELEVATED ZERO MAZE  
The elevated zero maze was used to test for anxiety in the mice, and account for 
any effects this could be have on other behavioral test outcome. An elevated zero apparatus 
was used from Maze Engineers (Boston, MA). Mice were placed on the maze at one of the 
four points, chosen randomly, where the open and closed arm meet. The test period began 
as soon as the mouse was set down and lasted five minutes. Noldus ethovision was used to 
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record and score the test. The time spent in open vs closed arms was scored and compared 
using a t-test.  
5.2.3 CARBON-FIBER MICROELECTRODES 
CFM’s were constructed through the aspiration of a single T-650 carbon fiber (7 
μm, Goodfellow, Coraopolis, PA) through a cylindrical glass capillary (internal diameter: 
0.4 mm, external diameter: 0.6 mm, Product # 624500, A-M Systems, Carlsborg, WA). 
This capillary was then placed in a vertical pipette puller (Narishige Group, Setagaya-Ku, 
Tokyo, Japan) to make a carbon – glass seal by gravity. The protruding carbon fiber was 
then cut to 150 μm in length. Subsequently, a solution of Nafion (LQ-1105-US-25, 5% by 
weight Nafion, Ion Power, DE) was electrodeposited, as previously described, onto the 
exposed carbon fiber 23. The CFM was then dried for 10 minutes at 70°C. 
5.2.4 ANIMAL SURGERY 
A urethane solution was produced (25% (w/v)) by dissolving urethane (Sigma 
Aldrich Co., St. Louis, MO, USA) in sterile saline (0.9% NaCl solution, Hospira, Lake 
Forest, IL). When the mice were 7 to 10 weeks old the urethane was administered 
intraperitoneally (i.p.) at a volume of 7 μL per 1 g mouse weight, followed by stereotaxic 
surgeries (Model 962, David Kopf Instruments, Tujunga, CA) during the light cycle. To 
maintain the ideal mouse body temperature of 37° C, a heating pad from Braintree 
Scientific was utilized. For stereotaxic coordinates of MFB [AP: -1.58, ML: +1.0, DV: -
4.8 to -5.0] and mPFC [AP: +1.7, ML: +0.2, DV: -2.0 to -3.0], bregma was used as a 
reference from Franklin and Paxinos (2008). In order to access the MFB and mPFC, holes 
were drilled in line with the above stereotaxic coordinates. For stimulation, a stainless-steel 
electrode (diameter 0.2 mm, MS303/2-A/SPC; Plastics One, Roanoke, VA) was inserted 
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into the MFB. For measurements, the Nafion-coated CFM was inserted into the mPFC. 
The reference electrode is made of a silver wire (diameter: 0.010 in, 787000; A-M Systems, 
Sequim, WA), which was electroplated with chloride through immersion of in hydrochloric 
acid for 30 seconds (0.1 M, 4 V vs. tungsten). This is then placed into the contralateral 
hemisphere of the CFM placement. 
5.2.5 DATA COLLECTION AND ANALYSIS 
FSCV was performed through instrumentation and software (WCCV 3.05) 
developed by Knowmad Technologies LLC (Tucson, AZ); the “Jackson” waveform 20 was 
applied for the measurement of serotonin. Measurements were collected every 10 minutes 
with a 30 second file. Five seconds into the file, a stimulation was applied (60 Hz biphasic 
360 μA, 120 pulse stimulation, 2 ms per phase) using a linear constant current stimulus 
isolator (NL800A Neurolog; Digitimer Ltd.) to elicit the serotonin response. Signals were 
processed using custom software (vide supra) using LabVIEW 2009. The processing used 
includes signal deconvolution, filtering, and smoothing.  
Signals were analyzed to compare the maximum amplitude and t1/2. The maximum 
amplitude was taken as the highest concentration of serotonin elicited following the 
stimulation. The t1/2 was calculated using the curve fitting tool with a custom equation for 
plotting exponential decay in MatLab R2018B, the natural log of 2 was divided by the 
mean lifetime yielded to calculate t1/2.  
5.2.6 EXCLUSION CRITERIA 
For all FSCV experiments, the CV of the evoked signal was compared to well-
established serotonin cyclic voltammograms (CVs) in vivo and in vitro and mice in which 
the CVs did not contain the characteristic serotonin redox peaks were excluded. For 
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FSCAV experiments, a stimulated serotonin response was collected prior to the start of 
FSCAV and the same aforementioned test was performed. Data which contained a peak 
resulting from the stimulation electrode touching the skull that masked, delayed, or 
minimized the serotonin response (stimulation glitch) were excluded. Electrodes that 
displayed instability during file collection were excluded.  
5.2.9 HISTOLOGY 
In order to confirm the spatial placement of the CFM in vivo, a small lesion was 
created at the end of the FSCV experiment, by applying a constant potential at the CFM 
(~10 V for 1 min). Subsequently, the mice were euthanized via cervical dislocation 
followed by decapitation, and the brain was removed from the skull and stored in 4% 
paraformaldehyde in PBS solution. At least 2 days prior to sectioning, the brain was 
transferred into a 30% sucrose solution, until it was saturated with the medium. The brain 
was then flash-frozen, sectioned into 30 μm slices mounted onto frosted glass slides. The 
slices were then photographed with an optical microscope. 
5.3 RESULTS  
5.3.1 ACUTE RESPONSE 
 The administration of a bolus injection of 15 ppb Pb2+ caused a slight reduction in 
evoked serotonin amplitude 60 minutes following the injection, as seen in Figure 5.1. This 
reduction was not consistent in every animal and to determine if the reduction was 
significant the maximum amplitude of the file collected 60 minutes after Pb2+ 
administration was compared to the maximum amplitude of the control files (of which 
there were four). A q-test was used to determine if the change in amplitude following Pb2+ 
injection was significantly different, and the results are displayed in Table 5.1. The t½ was 
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calculated as the time it takes for the serotonin signal to decay to half of its maximum 
amplitude. The comparison process using a q-test was repeated for t½, shown in Table 5.1, 
though only one animal displayed significantly slowed reuptake while the other three 
display non-significant faster or slower reuptakes. 
 
 
Figure 5.1. Evoked Serotonin Release Pre and Post-Acute 
Pb2+ Administration. The average evoked serotonin release 
(stimulation is noted by the yellow box) is shown in blue 
along with the evoked serotonin release 60 minutes following 
the injection of a bolus dose of 15 ppb Pb2+ (n=4). 
 


















Acute 1 27.71± 1.22 21.72 0.628 2.04±0.113 1.98 0.0848 
Acute 2 40.24 ± 1.29 29.95 1.19 2.19±0.227 1.90 0.0126 
Acute 3 33.61 ± 0.44 27.92 1.92 1.27±0.0693 1.85 1.25 






5.3.2 CHRONIC ADULT EXPOSURE 
Mature mice were exposed to 15 ppb Pb2+ in their drinking water for one week, 
while control mice received filtered water from animal facilities, that is free of Pb2+. The 
evoked serotonin signals in these animals were compared in Figure 5.2. While the chronic 
Pb2+ exposure mice appeared to have slightly lower amplitude of evoked serotonin, this 
difference was not significant, as determined with a t-test (p=0.355). The reuptake of 
serotonin was also compared between the two groups by evaluating the t½ as the time to 
reach half of the maximum amplitude. There was no significant difference in the t½ between 
the chronic Pb2+ exposure mice and the controls, as determined by a t-test (p=0.247). It 
should be noted that the comparison of the chronic exposure here is complicated by not 
knowing the starting point of the serotonin signals in the individual animal and at the 
specific electrode location. The serotonin response varies between each mouse and has a 
range of evoked concentration of approximately 10-45 nM with the single peak alone. 
Therefore, it is probable that only drastically different serotonin responses will be 
discovered without exceedingly large sample size. 
 
Figure 5.2. Evoked Serotonin Release in Chronic Pb2+ Exposed 
Mice and Controls. The average evoked serotonin release 
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(stimulation is noted by the yellow box) of control (blue, n=4) 
and chronic Pb2+ exposure (red, n=4) mice are shown here.  
 
5.3.3 PERINATAL EXPOSURE 
Breeding pairs were exposed to 15 ppb Pb2+ in drinking water until the pups were 
weaned at 21 days. When the mice reached maturity, they underwent a series of behavior 
tests to evaluate whether the mice displayed stereotypical ASD behaviors. The results of 
this tests are seen in Figure 5.3. The mice exposed to Pb2+ during development did not 
display any differences from controls in the three chamber social approach task (Figure 5.3 
Panel A), particularly they did not display less preference for the chambers that contained 
either a familiar (t-test, p=0.362) or novel mouse (t-test, p=0.494) when compared to the 
control mice. The mice did not display other changes to their social communication on the 
olfactory habituation/dishabituation test (Panel D), displaying interest for the social scent 
and the non-social scent equivalent to that of the control mice (ANOVA, p=0.422, 
p=0.0742, respectively). The exposed mice also demonstrated significantly more interest 
for the social scents than the non-social scents (ANOVA, p=0.0003), as did the control 
mice (ANOVA, p=0.000). The exposure mice did not display significantly increased 
anxiety on the elevated zero test (Panel B), spending only slightly more time on average in 
the open arms of the apparatus than the control mice (t-test, p=0.0799). Finally, analysis 
for repetitive behaviors finds that in the marble burying test (Panel C) the Pb2+ exposed 
mice did not bury significantly more marbles compared to controls (t-test, p=0.246). The 
only behavior found to be statistically different when grooming, digging, rearing, and 
climbing were scored over a 15-minute period was climbing, with exposed mice climbing 
significantly less than controls (t-test, p= 0.00238). Exposed mice did appear to rear more 
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Figure 5.3. Behavioral Outcomes of Perinatal Pb2+ Exposed Mice. Perinatal Pb2+ exposed 
mice (yellow) are compared to control mice (blue) across five different behavioral tests. 
The three chamber social approach (A), elevated zero (B), marble burying (C) and olfactory 
habituation/dishabituation (D) found no significant differences between exposed and 
control mice. The repetitive behavior test found that exposed mice displayed less climbing 
behavior than control mice (t-test, p= 0.00238). (exposure n=22, control n=18) 
 
Several days following the conclusion of the behavior tests, mice underwent 
stereotaxic surgery and were evaluated for difference in their serotonin neurochemistry. 
The average evoked serotonin response of the perinatal exposure mice was compared to 
that of controls, shown in Figure 5.4. The two main features of the curve, maximum 
amplitude and t½, were compared using a t-test and significant differences were not found 





Figure 5.4. Evoked Serotonin Release in Perinatal Pb2+ Exposed 
Mice and Controls. The average evoked serotonin release 
(stimulation is noted by the yellow box) of control (blue, n=7) and 
perinatal Pb2+ exposure (yellow, n=7) mice are shown here. 
 
Table 5.2. Comparison of MaxA and t½ of Perinatal Pb
2+ Exposure Mice and Control Mice. 
  
Experiment MaxA (nM) T1/2 (s) 
Exposure 1 20.61 0.879 
Exposure 2 9.05 1.04 
Exposure 3 11.74 1.31 
Exposure 4 9.50 1.88 
Exposure 5 35.26 1.17 
Exposure 6 29.18 1.21 
Exposure 7 22.83 1.61 
Control 1 8.85 1.98 
Control 2 25.99 2.18 
Control 3 8.79 1.12 
Control 4 17.49 1.56 
Control 5 18.48 0.943 
Control 6 17.16 1.85 
Control 7 24.48 1.49 











5.4.1 AUTORECEPTOR AND TRANSPORTER ALTERATIONS  
 The evoked serotonin curve obtained with FSCV can inform upon several 
regulation mechanisms of serotonin transmission. The aspects which we have evaluated in 
this work via analysis of the maximum amplitude and t½ are amount released (as a function 
of serotonin synthesis, vesicular packaging, receptors, and input strength) and rate of 
reuptake (via transporters)21, 73. The reduction in amplitude following the acute 
administration of Pb2+ suggests that there may be either direct or indirect effects on the 
autoreceptors. 
There are 7 known serotonin receptor families, most with multiple subtypes, that 
can act in an excitatory or inhibitory role for serotonin release4. We observe their effects 
on evoked serotonin curves in two areas: the maximum amplitude of serotonin released 
and a dip in the concentration below baseline following stimulation as a function of 
prolonged inhibition21. As the stimulation occurs, serotonin axons release serotonin into 
the extracellular space where it binds to receptors and gets taken up by transporters. Once 
the serotonin binds to the receptor it can inhibit the maximum amplitude observed in two 
ways, the receptor may inhibit the release of serotonin, as the 5HT1A autoreceptor does
114, 
or it may regulate the serotonin transporter (SERT) and can initiate a faster reuptake of 
serotonin, as the 5HT1B receptor does
94. The maximum amplitude observed is a summation 
of released serotonin and the simultaneous reuptake of serotonin by transporters93. The 
transporter function is typically evaluated as the rate of reuptake of serotonin and can be 
quantified by the time it takes to reach half of the maximum amplitude, t½. The receptors 
in particular can be subject to changes via Pb2+ since this metal mimics and competes with 
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Ca2+ 100. When the receptors bind to serotonin, they cause ion channels to open allowing 
for the influx of specific ions. Any differences in how Pb2+ performs once inside the cell 
could affect serotonin inhibition or excitation and may explain the changes in amplitude 
observed.  
5.4.2 INFLAMMATION RESULTING FROM PB2+ EXPOSURE  
The effects of Pb2+ in the brain are numerous and wide reach, therefore it warrants 
further consideration of an indirect cause of the alterations observed following Pb2+ 
administration. Pb2+ has been observed to cause microgliosis and astrogliosis, indicating a 
potent neuroinflammatory response112. Since immune responses are unique to each 
individual animal the theories described below may also explain why only some of the 
animals exhibited statistically lower serotonin signals since each mouse would be subject 
to a variable inflammatory response.  
Inflammation, particularly neuroinflammation, has been found to result in higher 
histamine levels115. We have shown in previous work that histamine acts to modulate 
serotonin via the H3 receptor, resulting in an inhibition of serotonin when histamine levels 
are higher110. This is one possible theory as to why the serotonin release is lower following 
Pb2+ administration.  
Research has shown that the extracellular fluid is reduced during inflammation 
states which would result in a higher concentration of neurotransmitters, serotonin 
included, in the extracellular space116. This higher concentration may be causing the 
autoreceptors to activate, thus further inhibiting the release and increasing the uptake.  If 
the extracellular level is already above what it normally would be due to inflammation, the 
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autoreceptors would activate at a lower stimulated release of serotonin. This provides an 
addition theory for the decreased summation of serotonin release observed. 
5.4.3 CHRONIC AND PERINATAL SEROTONIN EFFECTS 
 The chronic and perinatal effects observed are more inconsistent than the acute 
responses to Pb2+, with no statistical difference in variations in uptake or amplitude. This 
uncertainty is primarily due to a limitation with looking at effects to serotonin following 
long-term exposures using FSCV. It is more difficult to view changes to serotonin with this 
technique following long-term exposures because we do not know the starting point of the 
individual animal and electrode location. Bearing this in mind and as no dramatic 
differences have been observed, we will assume that the alterations are negligible since the 
signals observed still fall within the range of controls.  
 Acute effects indicate that after a single dose, alterations to serotonin are possible. 
Based upon this, we assumed that longer-term exposures would elicit more dramatic 
changes. However, as that does not appear to be the case for either chronic or perinatal 
exposure, we must assume that the serotonin system has compensated for these changes to 
maintain equilibrium. It is not surprising that the compensations are made for longer-term 
exposures since serotonin is very tightly regulated in the brain and falling out of its narrow 
range of operation can have severe, even deadly consequences39, 117.  
 In the case of the perinatal exposure, the low dose utilized was either not enough to 
result in the altered gene expression observed in other studies at higher exposure doses, or 
the serotonin system was able to compensate for these changes in inflammatory response. 
It must also be noted that our technique reveals only evoked serotonin and that changes in 
basal serotonin could still be present and should be investigated in the future. 
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 The general lack of behavioral changes following perinatal exposure are 
unsurprising as the dose utilized was much lower than any previously reported to have 
behavioral changes. There are some trends, such as more rearing observed and less anxiety 
displayed, that may prove to be significant with a slightly larger cohort. Nonetheless, at 
this time we must assume that perinatal exposure to 15 ppb Pb2+ is not substantial enough 
to induce any stereotypical ASD behaviors.  
5.4 CONCLUSION 
We observed variable but significant effects of 15 ppb Pb2+ exposure on serotonin 
transmission during an acute administration. This effect was not preserved or exacerbated 
during chronic or perinatal exposures. We also found no significant behavioral changes to 
suggest that Pb2+ perinatal exposure at only 15 ppb induces stereotypical ASD behaviors.  
To better understand the acute effects of Pb2+ a higher concentration of Pb2+ must 
be utilized, potentially revealing a more consistent and severe reduction in amplitude. 
Additionally, expanding the sample size may result in statistical significance across the 
average of the animals. Discerning which of the proposed theories holds the most weight 
would best be accomplished by evaluating the basal serotonin concentrations and also 
assessing markers of inflammation in each of the mice. This data combined with the FSCV 
signals would present a more complete picture of what is happening to alter serotonin 
neurotransmission. It would also indicate if the chronic and perinatal exposures are being 
affected by inflammation at this low dose and what regulatory mechanisms have been 
employed to reinstate equilibrium in the serotonin system. 
The serotonin system is perhaps more robust and adaptive to outside influence than 
we initially assumed. The main concern raised by this study is that if there are effects on 
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serotonin transmission following one dose of Pb2+ at the EPA drinking water standard, 
albeit variable, what are the consequences for dose much higher than this such as those 
resulting from cases in Flint, MI and D.C.? The serotonin system proves to be resilient and 
adaptive following a long-term exposure to Pb2+, but this may reach a breaking point at 
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CHAPTER 1 SUPPLEMENTARY MATERIAL 
 
  
   
Figure A.1 mPFC Double Peak Response to Escitalopram. An additional representative 
plot of a serotonin double peak control (blue) signal and ESCIT (red) response in layers 5-




Figure A.2 Histology of Experiments. A physical representation of the histology for each 
data point, corresponding to the data in Table 1. The location of the lesion can be identified 
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by the yellow dot. A representative stained slice is shown with the lesion appearing in the 




Figure A.3 mPFC Single Peak Response to Escitalopram. An additional representative plot 
of a serotonin single peak control (blue) signal and ESCIT (red) response in layers 1-3 of 
the mPFC. A second peak is induced following the administration of ESCIT.  
 
 
Figure A.4 The basal concentration of serotonin in the mPFC (n=5) as determined by fast-
scan controlled adsorption voltammetry (FSCAV). The region has a range from 55-75 nM 




CHAPTER 2 SUPPLEMENTARY MATERIAL 
 
Table B.1 Preliminary Study Data Used for the Power Analysis 
 Max Amplitude 
Animal 1  
Control 0.645 
Drug Effect 2.01 
Animal 2  
Control 1.39 
Drug Effect 2.54 
Animal 3  
Control 1.36 
Drug Effect 2.86 
Animal 4  
Control 1.03 
Drug Effect 2.60 
Animal 5  
Control 1.47 
Drug Effect 5.72 
  
 Average± Std Dev 
Control 1.18±0.34 












Chapter 3 Release. Screenshots obtained at: 
 https://onlinelibrary.wiley.com/page/journal/14714159/homepage/permissions.html 
 
